Conjugation of adeno-associated viruses

By inserting the sorting enzyme recognition sequence in a specific region of the AAV capsid protein, conjugated AAV particles are formed, and the transduction efficiency and immune response problems of existing AAV gene therapy vectors are solved, achieving more efficient and specific targeting Transduction and reduce preparation costs.

CN119095973APending Publication Date: 2024-12-06TAVIRA THERAPEUTICS BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035378.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-28
Filing Date
2023-04-28
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing AAV gene therapy vectors have shortcomings in transduction efficiency and immune response, resulting in high dose demand and safety risks, and are expensive to prepare and difficult to achieve clinical application.

Method used

Conjugated AAV particles are formed to improve target specificity and transduction by inserting sorting enzyme recognition sequences into the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region of the AAV capsid protein. and maintain similar preparation efficiency.

Benefits of technology

More efficient and specific targeted transduction is achieved, which reduces off-target transduction effect and preparation cost, improves the transduction spectrum of AAV particles, and enhances the targeting ability to specific tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005094043570000281
    Figure BDA0005094043570000281
  • Figure BDA0005094043570000401
    Figure BDA0005094043570000401
  • Figure BDA0005094043570000402
    Figure BDA0005094043570000402
Patent Text Reader

Abstract

The present invention relates to adeno-associated virus (AAV) VP1, VP2 or VP3 capsid proteins characterized by sortase recognition of one or more of insertion of the VP1-VP2 transition region, the VR-I region, the VR-IV region and the VR-VIII region, where n and m range from 0 to 25, and where X is any natural amino acid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates broadly to the field of gene therapy. In particular, the present invention relates to a technique for conjugating heterologous molecules such as targeting molecules to AAV capsids in a controllable manner. Background Art

[0002] Gene therapy (GT) is a treatment modality that involves the addition of transgenes to alter cellular physiology to treat or prevent disease. This innovative technology uses viral vectors to correct or replace defective genes that cause disease. Gene therapy holds great promise in treating rare and more complex devastating diseases for which there are currently no cures.

[0003] Adeno-associated virus (AAV) is a small, non-pathogenic virus that is currently the main gene delivery vector in gene therapy. AAV has a wide range of tissue tropism, is not related to disease phenotype, and is not highly immunogenic. In addition, AAV has the potential to provide long-term therapeutic effects after a single dose.

[0004] Recombinant AAV (rAAV) is an engineered version of the virus in which viral genes are placed in trans and replaced by a transgene of approximately 4.5 kb. Although rAAV-based GT products have generally been shown to be safe and effective, they do have some drawbacks. For example, the underlying transduction process, i.e., cellular entry into target tissues, uncoating, and expression of the therapeutic payload of viral particles within target cells, is inefficient, requiring large doses of the vector to achieve a therapeutic effect. Following systemic administration, this can lead to accumulation in the liver and immune responses to the therapeutic vector. Importantly, high doses of rAAV have been associated with severe adverse events such as hepatotoxicity and thrombotic microangiopathy, and have led to the death of some patients in AAV GT trials. In addition, depending on the AAV serotype, 40-70% of the population carries AAV neutralizing antibodies. These antibodies contribute to the observed immune responses, reduce efficacy, and prevent re-administration of GT products, resulting in seropositivity becoming an exclusion criterion for many GT trials. In addition to these biological issues, the cost of preparing large quantities of high-purity rAAV products is high, and the production capacity is extremely scarce.

[0005] One of the most promising approaches to address these problems is to design novel capsids that exhibit improved immune escape and transduction properties. By narrowing the broad tropism of naturally occurring AAV vectors to specific tissues or cell types through capsid engineering, rAAV products become more potent, allowing for lower doses of treatment. This reduces safety risks and manufacturing costs. However, despite a lot of effort in capsid engineering (e.g., directed evolution capsid design platform), no breakthrough innovation has been verified in the clinic. This is partly due to the fact that the broad tropism of AAV serotypes found in nature is used as the starting material for directed evolution library generation, the difficulty of preparing novel rAAV serotypes, and the need to screen capsid libraries in rodents and non-human primates (NHPs), which is an obstacle to human translation.

[0006] A promising approach to designing capsids with improved specificity for target tissues and lower off-target transduction without compromising manufacturing is to conjugate AAV particles with specific (re)targeting groups at a post-manufacturing stage. Some research groups have genetically integrated targeting groups into capsid proteins or conjugated them to adapter molecules that allow covalent or non-covalent attachment of AAV particles after purification. These rAAV conjugates show higher transduction efficiency for specific tissues with lower off-target effects, such as in the liver. However, the modifications required to the capsid often affect the yield. In addition, the low modularity and complex, often multi-component genetic or chemical design devices make these systems largely incompatible with current commercial manufacturing practices. Recently, capsid proteins have been genetically fused to nanobodies, which improves targeting. However, the targeting efficiency is largely dependent on the specific AAV-nanobody construct. This can be traced back to the unpredictable folding and quaternary structure formation of modified AAV virions, as well as the unknown effects of nanobody fusion on the supramolecular dynamics caused by direct genetic integration of nanobodies. Furthermore, gene insertions of large protein moieties can negatively impact the efficiency of affinity purification using commercially available resins.

[0007] In summary, conjugating AAV to targeting groups is a promising strategy to improve the transduction profile of rAAV particles for gene therapy, but current approaches lack the design and / or performance qualities required for commercial gene therapy products and face significant manufacturing barriers. For clinical and commercial success, better AAV conjugation methods are urgently needed. Summary of the invention

[0008] Through a large number of experiments, the inventors found that the sortase recognition sequence can be introduced into the interior of the AAV particle capsid sequence to conjugate the targeting molecule to the AAV capsid, thereby producing conjugated AAV particles and targeting tissues and cells more efficiently and specifically. Surprisingly, contrary to the general consensus in the field of molecular biology and biotechnology that the sortase recognition sequence typically uses the C-terminus, the inventors found that the insertion of the sortase recognition sequence in the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region maintains the structural integrity of the one or more regions after undergoing the sortase reaction. The use of internal sortase recognition sequences is particularly valuable for generating a new "generation" of customized AAV particles with improved properties (e.g., more effective and more specific targeting of target tissues and cells). In addition, the molecular design considerations made by the inventors allow for increased modularity of AAV production methods and platforms while maintaining similar production efficiency compared to the appropriate parent AAV serotype.

[0009] Therefore, one aspect of the present invention provides an adeno-associated virus (AAV) capsid protein, characterized in that a sortase recognition sequence is inserted into one or more of the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region. In certain embodiments, the sortase recognition sequence has a universal sequence motif selected from the group consisting of: Xn-LPXTG-Xm [SEQ ID NO: 10], Xn-NPXTG-Xm [SEQ ID NO: 40], Xn-LPXTA-Xm [SEQ ID NO: 41], Xn-LAXTG-Xm [SEQ ID NO: 42], Xn-LPXAG-Xm [SEQ ID NO: 48], Xn-LPXLG-Xm [SEQ ID NO: 49], Xn-APXTG-Xm [SEQ ID NO: 50], Xn-LPXSG-Xm [SEQ ID NO: 51], Xn-FPXTG-Xm [SEQ ID NO: 52], Xn-XPKTG-Xm, [SEQ ID NO: 53] and Xn-LPEXG-Xm, [SEQ ID NO: 54]. NO:54], wherein n and m range from 0 to 25, and wherein X is any natural amino acid selected independently of Xn and Xm. Preferably, the (AAV) VP1, VP2 or VP3 capsid protein is characterized by the sortase recognition sequence Xn-LPXTG-Xm [SEQ ID NO:10] inserted into one or more of the VR-I region, VR-IV region and VR-VIII region, wherein n and m range from 0 to 25, and wherein X is any natural amino acid. Optionally, n and m range from 0 to 20. Preferably, X is glutamic acid (E) or glutamine (Q).

[0010] In certain embodiments, in the corresponding amino acid sequence of AAV2 or another AAV serotype, the VP1-VP2 transition region is defined by SEQ ID NO: 1 [PVKTAP], the VR-I region is defined by SEQ ID NO: 2 [SSQSGASN], the VR-IV region is defined by SEQ ID NO: 3 [SRTNTPSGTTTQSRLQFSQAGASDIRDQS], and the VR-VIII region is defined by SEQ ID NO: 4 [QYGSVSTNLQRGNRQAATADVNTQGV].

[0011] In certain embodiments, the insertion in the VR-IV region is located in a fragment having SEQ ID NO: 5 [TPSGTTTQS] and / or the insertion in the VR-VIII region is located in a fragment having SEQ ID NO: 6 [LQRGNRQAA] in the corresponding amino acid sequence of AAV2 or another AAV serotype.

[0012] In certain embodiments, in the region where the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted, one or more amino acids in the region are deleted, and / or one or more amino acids in the region are substituted.

[0013] Optionally, the AAV is AAV2 or AAV9.

[0014] Optionally, n is between 15 and 20, or between 10 and 15, or between 5 and 10, or between 0 or 5, or 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1. Preferably, n is from 5 to 20, preferably from 5 to 15, more preferably from 10 to 15.

[0015] Optionally, m is between 15 and 20, or between 10 and 15, or between 5 and 10, or between 0 or 5, or 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1. Preferably, m is between 5 and 20, preferably between 5 and 15, more preferably between 10 and 15.

[0016] In certain embodiments, the linker sequence Xn or Xm is composed of at least 80% of glycine (Gly), serine (Ser), threonine (Thr) and alanine (Ala). Preferably, the linker sequence Xm or Xn is composed of an amino acid selected from glycine (Gly), serine (Ser), threonine (Thr) and alanine (Ala).

[0017] In certain embodiments, X in LPXTG is aspartic acid (Asp), glutamic acid (Glu), asparagine (Asn) or glutamine (Gln), preferably glutamine (Gln).

[0018] In certain embodiments, one or more lysine (K) of the AAV capsid protein is mutated to glycine (Gly), serine (Ser), or alanine (Ala).

[0019] A further related aspect of the invention relates to a nucleic acid encoding a capsid protein according to any of the embodiments described herein.

[0020] However, a further related aspect of the invention relates to an expression vector comprising a nucleic acid according to the above aspects.

[0021] A further related aspect of the invention relates to AAV particles. In particular, the AAV particles comprise an AAV capsid protein having a sortase recognition sequence inserted into one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region, and the VR-V-VIII region. Both AAV particles before the sortase conjugation reaction and after the sortase conjugation reaction (i.e., conjugated AAV particles) are contemplated. Therefore, another aspect of the invention relates to AAV particles comprising an AAV capsid protein according to any of the above embodiments. In addition, another related aspect of the invention relates to conjugated AAV particles comprising an AAV capsid protein, the AAV capsid protein being characterized by a residual sortase recognition sequence (i.e., a modified sortase recognition sequence present after the conjugation reaction) in the VP1-VP2 transition region, the VR-I region, the VR-IV region, and / or the VR-VIII region, and wherein the residual sortase recognition sequence is operably linked to a heterologous conjugated molecule.

[0022] In certain embodiments, the conjugated AAV particle is operably linked (ie, fused) to a heterologous conjugate molecule via a sortase recognition sequence, preferably wherein the conjugate molecule is characterized by the presence of a terminal triglycine amino acid sequence. Optionally, the heterologous conjugate molecule is a small molecule, a carbohydrate, a lipid, or a polypeptide.

[0023] In certain embodiments, the conjugated AAV particles are operably linked (i.e., fused) to a targeting moiety via a sortase recognition sequence. Optionally, the targeting moiety is a ligand of a cell receptor or a protein that binds to a cell surface protein. Optionally, the protein that binds to a cell surface protein is an antibody or nanobody. Optionally, the antibody or nanobody specifically binds to HER2.

[0024] Yet another aspect of the present invention relates to the use of the conjugated AAV particle according to any of the embodiments described herein as a medicament.

[0025] A related aspect of the above embodiments of the invention relates to methods of preparing conjugated AAV particles as described herein. In a specific embodiment, the method of preparing conjugated AAV particles comprises the following steps:

[0026] - contacting a cell with one or more nucleic acids encoding an AAV capsid protein, wherein one or more of the VP1-VP2 transition region, VR-I region, VR-IV region, or VR-VIII region of the AAV capsid protein comprises a sortase recognition sequence;

[0027] - allowing the cells to assemble multiple AAV capsid proteins into AAV particles and collecting the AAV particles from the cells; and

[0028] - Contacting the sortase and the heterologous conjugate molecule with the AAV particles.

[0029] The above and other aspects and preferred embodiments of the present invention are described in the following sections and in the appended claims. The subject matter of the appended claims is hereby specifically incorporated into this description. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 :(A) Schematic diagram of the gene construction of wild-type AAV (wtAAV) and recombinant AAV (rAAV). (B) Schematic representation of the mechanism of sortase A

[0031] Figure 2 : (A) Schematic overview of the VP1, VP2, VP3 proteins and the VP1-VP2, VR-I, VR-IV and VR-VIII regions. (B) General representation of the internal LPQTG motif flanked by linker sequences.

[0032] Figure 3 : LPQTG motif inserted into AAV2-HB0 VR-IV (between AA 453 and 454) VR-VIII (between AA587 and 588), motif A band consistent with the molar mass of the N-terminal fragment of VP3 conjugated with Nb (~19 kDa) can be seen in VIII-1 and VIII-2 without linker or with 1 or 2 GGSGS [SEQ ID NO:47] repeats on either side, indicating conjugation reaction. Srt-A: Sortase A only, Nb: Nanobody only

[0033] Figure 4 : AAV2, VR-I, 0-1-2L. AAV2-HB0 with a LPQTG tag [SEQ ID NO: 43] at position 265, flanked by 0, 1 or 2 GGSGS [SEQ ID NO: 47] linkers. Arrows: conjugated products.

[0034] Figure 5: AAV2, VR-IV, 0-1-3-4-5L. AAV2-HB0 with a LPQTG tag [SEQ ID NO: 43] at position 453, flanked by 0, 1, 3, 4 or 5 GGSGS [SEQ ID NO: 47] linkers. Arrows: conjugated products.

[0035] Figure 6 : AAV2, VR-VIII 0-1-2-3-4-5L. AAV2-HB0 with a LPQTG tag [SEQ ID NO: 43] at position 587, flanked by 0, 1, 2, 3, 4 or 5 GGSGS [SEQ ID NO: 47] linkers. Arrows: conjugated products.

[0036] Figure 7 : AAV9, VR-IV 0-1-2-31. AAV9-A with a LPQTG tag [SEQ ID NO: 43] at position 455, flanked by 0, 1, 2 or 3 GGSGS [SEQ ID NO: 47] linkers. Arrows: conjugated products.

[0037] Figure 8 : AAV9, VR-VIII 0-1-3L. AAV9-A with a LPQTG tag [SEQ ID NO: 43] at position 589, flanked by 0, 1 or 3 GGSGS [SEQ ID NO: 47] linkers. Arrows: conjugated products.

[0038] Fig. 9 : Comparison of 5 different constructs. AAV2-HB0, which has a LPQTG tag at position 265 (SEQ ID NO: 43), with 2 GGSGS (SEQ ID NO: 47) linkers on both sides of the tag; AAV2-HB0, which has a LPQTG tag at position 453, with 3 GGSGS (SEQ ID NO: 47) linkers on both sides of the tag; AAV2-HB0, which has a LPQTG tag at position 587 (SEQ ID NO: 43), with 3 GGSGS linkers on both sides of the tag; AAV9-A, which has a LPQTG tag at position 455 (SEQ ID NO: 43), with 3 GGSGS (SEQ ID NO: 47) linkers on both sides of the tag; AAV9-A, which has a LPQTG tag at position 589 (SEQ ID NO: 43), with 3 GGSGS (SEQ ID NO: 47) linkers on both sides of the tag. Arrows: conjugated products.

[0039] Fig.10: GGG-biotin. AAV2-HB0, which has a LPQTG tag [SEQ ID NO: 43] at position 587, with a GGSGS [SEQ ID NO: 47] linker on both sides of the tag.

[0040] Fig.11 : HER2 and GFP. AAV2-HB0, which has a LPQTG tag at position 453 (SEQ ID NO: 43), with three GGSGS (SEQ ID NO: 47) linkers on both sides of the tag, and AAV9-A, which has a LPQTG tag at position 589, with three GGSGS (SEQ ID NO: 47) linkers on both sides of the tag. Arrow: conjugated product.

[0041] Fig.12 : LPQTG and LPETG in AAV2_VR-VIII and AAV9_VR-IV. AAV2-HB0, which has a LPQTG tag (SEQ ID NO: 43) at position 587, with three GGSGS (SEQ ID NO: 47) linkers on both sides of the tag; AAV2-HB0, which has a LPETG tag [SEQ ID NO: 44] at position 587, with three GGSGS (SEQ ID NO: 47) linkers on both sides of the tag; AAV9-A, which has a LPQTG tag (SEQ ID NO: 43) at position 455, with three GGSGS [SEQ ID NO: 47] linkers on both sides of the tag; AAV9-A, which has a LPETG tag (SEQ ID NO: 44) at position 455, with three GGSGS (SEQ ID NO: 43) linkers on both sides of the tag. Arrows: conjugated products.

[0042] Fig.13 : In vitro targeting. AAV2-HB0, which has a LPQTG tag [SEQ ID NO: 43] at position 587, with three GGSGS [SEQ ID NO: 47] linkers on both sides of the tag. (A) Percentage of transduced cells, (B) Percentage of transduced cells (enlarged from (A)), (C) flow cytometry results.

[0043] Fig.14 : Comparison of transduction efficiency of different AAV vectors conjugated with anti-HER2 nanobodies relative to unconjugated vectors. Transduction efficiency was determined by GFP fluorescence.

[0044] Fig.15: Comparison of production yields of different constructs. (A) Average viral genome ("Vg") yield (left Y-axis) and % full viral particles (right Y-axis; black dots) in lysates of production cell cultures. (B) Average viral genome ("Vg") yield (left Y-axis; black dots) and % full viral particles (right Y-axis) in supernatants of production cell cultures.

[0045] Detailed description

[0046] As used herein, the singular forms "a," "an," and "the" include both singular and plural referents, unless the context clearly dictates otherwise.

[0047] As used herein, the terms "comprising," "comprises," and "comprised of" are synonymous with "including," "includes," or "containing," "contains," and are inclusive or open-ended and do not exclude additional, unrecited members, elements, or method steps. The terms also encompass "consisting of" and "consisting essentially of," which have established meanings in patent terms.

[0048] Numerical ranges recited by endpoints include all numbers and fractions contained in the corresponding ranges, as well as the recited endpoints. This applies to numerical ranges regardless of whether they are introduced by the expression "from ... to ... ", by the expression "between ... and ... ", or by another expression.

[0049] The terms "about" or "approximately" as used herein in reference to measurable values ​​such as parameters, quantities, lengths of time, etc., are meant to encompass variations from and relative to the specified value, such as variations of + / -10% or less, preferably + / -5% or less, more preferably + / -1% or less, and still more preferably + / -0.1% or less of the specified value and relative to the specified value, as long as the variations are suitable for implementation in the invention disclosed herein. It should be understood that the value to which the modifier "about" or "approximately" refers is itself also specifically and preferably disclosed.

[0050] Although by way of further illustration, the term "one or more" or "at least one", e.g., one or more members or at least one member of a group of members, is itself explicit, the term specifically encompasses reference to any one of the members or any two or more of the members, e.g., any ≥3, ≥4, ≥5, ≥6, or ≥7 of the members, etc., as well as up to all of the members. In another example, "one or more" or "at least one" may refer to 1, 2, 3, 4, 5, 6, 7 or more.

[0051] This discussion of the background of the invention is included to explain the context of the invention. This should not be taken as an admission that any of the material referred to was published, known or part of the common general knowledge in any country before the priority date of any claim.

[0052] In the present disclosure, various publications, patents and published patent specifications are cited by explicit citation. All documents cited in this specification are fully incorporated into this article by reference. In particular, the teachings or parts of the documents specifically mentioned in this article are incorporated by reference.

[0053] Unless otherwise defined, all terms used to disclose the present invention, including technical and scientific terms, have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. By way of further guidance, term definitions are included to better understand the teachings of the present invention. When defining specific terms in conjunction with a particular aspect of the present invention or a specific embodiment of the present invention, the connotation or meaning is intended to apply to the entire specification, that is, also to the context of other aspects or embodiments of the present invention, unless otherwise defined. For example, embodiments for products also apply to corresponding features of methods and uses.

[0054] In the following paragraphs, different aspects or embodiments of the invention are defined in more detail. Each aspect or embodiment so defined may be combined with any one or more other aspects or embodiments, unless explicitly indicated to the contrary.

[0055] In particular, any feature indicated as being preferred or advantageous may be combined with any other feature indicated as being preferred or advantageous.

[0056] References to "one embodiment" and "an embodiment" in this specification refer to specific features, structures or characteristics described in conjunction with the embodiments in at least one embodiment of the present invention. Therefore, the appearance of the phrases "in one embodiment" and "in an embodiment" in different places throughout this specification do not necessarily all refer to the same embodiment. In addition, in one or more embodiments, specific features, structures or characteristics may be combined in any suitable manner, as will be apparent to those skilled in the art from this disclosure. In addition, although some embodiments described herein include some of those included in other embodiments but do not include other features, the combination of features of different embodiments is intended to be within the scope of the present invention and to form different embodiments, as will be understood by those skilled in the art. For example, in the appended claims, alternative combinations of the embodiments of the requirements are covered, as will be understood by those skilled in the art.

[0057] Unless otherwise indicated, all methods, steps, techniques and operations not specifically described in detail can be carried out and performed in a manner known per se, which is clear to the skilled person. For example, reference is made to standard manuals and the general background information described herein and the further references cited therein (e.g. Sambrook et al., Molecular cloning: a laboratory manual, ISBN 0879693096, 1989 and the corresponding updated 4th edition, Cold Spring Harbor Laboratory Press, 2012).

[0058] In general, the amino acid sequences and their numbering in the present invention refer to the AAV2 VP1 capsid sequence described in SEQ ID NO:7. The shorter VP2 and VP3 proteins retain the same numbering. It is further noted that the insertion of a sortase recognition sequence, the optional insertion of a linker sequence, and the deletion of amino acids in the capsid protein backbone result in polypeptides of different lengths. In addition, the amino acids of these polypeptides in the capsid protein backbone are still defined by SEQ ID NO:7. The sequence similarity between the AAV2 capsid protein and the capsid proteins of other AAV serotypes allows the identification of corresponding amino acids in sequence alignments according to SEQ ID NO:7. As an illustration, corresponding AAV9 positions are also mentioned throughout this specification.

[0059] The present invention is equally applicable to AAV capsid sequences different from SEQ ID: 7, 8 or 9, such as naturally occurring serotype variants and artificial modifications to change tropism. The variants may also occur within the VR region, such as R585A, R588A mutants. Therefore, the AAV2 positions disclosed herein are intended to cover the corresponding amino acid positions in other AAV serotype variants (naturally occurring and artificially generated) as well.

[0060] The term "protein" as used throughout this specification generally encompasses macromolecules containing one or more polypeptide chains, i.e., polymeric chains of amino acid residues connected by peptide bonds. The term may encompass natural, recombinant, semisynthetic or synthetically produced proteins. The term also encompasses proteins carrying one or more co-expression or post-expression modifications of one or more polypeptide chains, such as, but not limited to, glycosylation, acetylation, guanidation, phosphorylation, sulfonation, methylation, ubiquitination, signal peptide removal, N-terminal Met removal, etc. The term further includes protein variants or mutants that carry amino acid sequence variations relative to the corresponding native protein, such as amino acid deletions, additions and / or substitutions. The term contemplates both full-length proteins and protein portions or fragments, such as naturally occurring protein portions produced by processing of the full-length protein.

[0061] The term "polypeptide" as used throughout this specification generally includes a polymeric chain of amino acid residues connected by peptide bonds. Therefore, especially when the protein consists of only a single polypeptide chain, the terms "protein" and "polypeptide" are used interchangeably herein to refer to the protein. The term is not limited to any minimum length of the polypeptide chain. The term can cover natural, recombinant, semisynthetic or synthetically produced polypeptides. The term contemplates both full-length polypeptides and polypeptide portions or fragments, for example, naturally occurring polypeptide portions produced by processing of the full-length polypeptide.

[0062] The term "peptide" as used throughout this specification preferably refers to a short chain of amino acid residues linked by peptide bonds, comprising 50 amino acids or less, such as 45 or less, preferably 40 amino acids or less, such as 35 amino acids or less, more preferably 30 amino acids or less, such as 25 or less, 20 or less, 15 or less or 10 or less amino acids. There is no strict maximum length requirement and a peptide can still be considered a peptide. The term peptide can encompass natural, recombinant, semisynthetic or synthetically produced peptides, such as the polypeptides discussed above.

[0063] The term "amino acid" encompasses naturally occurring amino acids, naturally encoded amino acids or protein-generated amino acids, non-naturally encoded amino acids, non-naturally occurring amino acids, amino acid analogs, and amino acid mimetics that function similarly to naturally occurring amino acids, both in their D- and L-stereoisomers, as long as their structure permits the stereoisomer formula. Amino acids are referred to herein by their names, their commonly known three-letter codes, or the one-letter codes recommended by the IUPAC-IUB Biochemical Nomenclature Commission. "Naturally encoded amino acid" refers to an amino acid that is one of the 20 common amino acids, or pyrrolysine, pyrroline-carboxy-lysine, or selenocysteine. The 20 common amino acids are: alanine (A or Ala), cysteine ​​(C or Cys), aspartic acid (D or Asp), glutamic acid (E or Glu), phenylalanine (F or Phe), glycine (G or Gly), histidine (H or His), isoleucine (I or Ile), lysine (K or Lys), leucine (L or Leu), methionine (M or Met), asparagine (N or Asn), proline (P or Pro), glutamine (Q or Gln), arginine (R or Arg), serine (S or Ser), valine (V or Val), tryptophan (W or Trp) and tyrosine (Y or Tyr). Amino acid analogs are also included, in which one or more individual atoms are replaced by different atoms, isotopes of the same atom, or different functional groups.

[0064] "Encoding" is to be interpreted according to the common interpretation in the art, and thus indicates that a nucleic acid sequence, or one or more portions thereof, corresponds to a specific amino acid sequence, such as the amino acid sequence of one or more desired proteins or polypeptides, according to the genetic code of the organism in question, or corresponds to another nucleic acid sequence in a template-transcription product (such as RNA or RNA analog) relationship. Although modifications of amino acid positions and / or amino acid sequences are mentioned several times throughout this specification, it is clear that in embodiments where the AAV capsid protein is translated from a nucleic acid sequence, the modifications are introduced into the encoding nucleic acid sequence.

[0065] The term "nucleic acid" used throughout this specification typically refers to a polymer (preferably a linear polymer) of any length essentially consisting of nucleoside units. Nucleoside units typically include a heterocyclic base and a sugar group. Heterocyclic bases can especially include purine and pyrimidine bases, such as adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U) widely present in naturally occurring nucleic acids, other naturally occurring bases (e.g., xanthine, inosine, hypoxanthine) and chemically or biochemically modified (e.g., methylated), non-natural or derivatized bases. Nucleic acids can be double-stranded, partially double-stranded or single-stranded. When single-stranded, nucleic acids can be sense strands or antisense strands. In addition, nucleic acids can be circular or linear.

[0066] It should be understood that the technician is able to assess the sequence identity between sequences. Because the methods and tools for verifying the sequence identity between different amino acid or nucleic acid sequences are well known. The tools include (protein) BLAST, ClustalW2, SIM alignment tools, TranslatorX and T-COFFEE. Depending on the algorithm selection and parameters, the percentage of identity between two sequences may have slight differences. The term "sequence identity" as used in the present invention refers to the relationship between sequences at the nucleotide (or amino acid) level. The expression "% identity (%identical)" is determined by comparing the best aligned sequences (e.g., two or more) on a comparison window, wherein the sequence portion in the comparison window may contain insertions and / or deletions relative to the reference sequence for the best alignment of the sequence. The reference sequence does not contain insertions or deletions. The reference window is selected, and then the number of identical nucleotides (or amino acids) between the sequences in the determination window is divided by the number of nucleotides (or amino acids) in the window, and then multiplied by 100 to calculate "% identity (%identity)". Unless otherwise stated, sequence identity is calculated on the full-length reference sequence. An example procedure for determining the percent identity between a particular amino acid sequence and the amino acid sequence of a query polypeptide would entail using the Blast 2 sequence (Bl2seq) algorithm to align two amino acid sequences using appropriate algorithm parameters. The Blast 2 sequence (Bl2seq) algorithm is available as a web application or as a stand-alone executable program (Blast version 2.2.31+) on the NCBI website (www.ncbi.nlm.nih.gov). Examples of suitable algorithm parameters include: matrix = Blosum62, cost to open a gap = 11, cost to extend a gap = 1, expectation value = 10.0, word size = 3). It is readily understood by the skilled artisan that any sequence represented in a sequence database or in this specification may be a precursor of a peptide, polypeptide, protein or nucleic acid and may include portions separated from mature molecules.

[0067] Adeno-associated virus, often referred to as "AAV", refers to a non-pathogenic parvovirus consisting of a 4.7 kb single-stranded DNA genome within a non-enveloped icosahedral capsid. Both the full-length term and its abbreviation can be used to refer to the virus itself or its derivatives. The AAV genome contains three AAV promoters (i.e., p5, p19, and p40; the names refer to their relative map positions) that are responsible for the expression of two open reading frames encoding the rep and cap genes. The two rep promoters (p5 and p19), plus differential splicing of a single AAV intron, drive the rep genes to produce four rep proteins (Rep 78, Rep 68, Rep 52, and Rep 40). The different Rep proteins have different enzymatic properties that are involved in various aspects of viral replication. The cap gene is expressed from the p40 promoter and encodes three capsid proteins: viral protein 1 (VP1), viral protein 2 (VP2), and viral protein 3 (VP3) through alternative splicing and non-consensus translation start sites. VP1, VP2 and VP3 are involved in the encapsidation of AAV (i.e., VP1, VP2 and VP3 are AAV capsid proteins). Thus, VP1, VP2 and VP3 have overlapping sequences with VP3, which is completely contained in the VP2 sequence, which in turn is contained in VP1. The regions with the highest structural variation (VR) have been referred to in the art as VR-I to VR-IX. The present invention is directed to sequence manipulation within the VR-I, VR-IV and VR-VIII regions. In addition, the present invention encompasses sequence manipulation within the VP1-VP2 transition region (i.e., the region marking the end of the unique N-terminal VP1 portion unique to each VP protein and the N-terminus of the VP2 protein sequence). A single consensus polyadenylation site is located at map position 95 of the AAV genome. In addition, the open reading frame produces the assembly activation protein (AAP) as an alternative reading frame within the cap gene, which is a viral protein that localizes the AAV capsid protein to the nuclear membrane and plays a role in the capsid assembly process. The AAV genome contains inverted terminal repeats at both ends.

[0068] It should be understood that the term "AAV" as used herein includes all subtypes and / or serotypes (naturally occurring and recombinant forms; rAAV), unless otherwise required or explicitly stated. Therefore, the term "AAV" covers AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV and sheep AAV, or any combination thereof. The technician understands that the above indication refers to a subject that can be infected by the AAV. For example, primate AAV refers to an AAV that can infect primates. The genomic sequences of various AAV serotypes, their natural inverted terminal repeats (ITRs), Rep proteins, and capsid subunits have been described in the art. The sequences can be found in literature or public repositories, such as GenBank, UniProt, etc. The term "AAV" also encompasses mosaic AAV and chimeric AAV containing specially designed AAV capsid proteins that do not naturally occur in nature (including AAVs obtained by, for example, directed evolution). The genomic diversity between different serotypes has been described in the art to be mainly concentrated in the hypervariable regions (HVRs) of the viral capsid, which affects the tissue tropism of AAV. It is known to technicians that the tissue tropism of AAV vectors depends on other factors (i.e., parameters), such as cell surface receptors, cellular uptake, intracellular processing of AAV, nuclear delivery of AAV genomes, uncoating of AAV, and second-strand DNA conversion. Preferred AAV serotypes in the context of the present invention are AAV2 and AAV9, but it is envisioned that any embodiment described in the present invention is equally applicable to any AAV serotype, including mosaic AAV and chimeric AAV.

[0069] As used herein, the term "tropism" refers to the preferred targeting of a particular host species or a particular cell type within a host species by a virus (in this context by AAV). For some viruses, the tropism of a virus describes the relative preference of the virus. When compared to another virus, if the viruses prefer the same characteristics (e.g., the second virus is also more successful in infecting the same cells (i.e., the same cell type), even if the absolute transduction efficiency is not similar), a virus can be considered to have a similar (or identical) tropism as another virus. It may be that the second virus is more effective than the first virus in infecting each given cell type tested, but if the relative preferences are similar (or identical), the second virus is generally considered in the art to have a similar (or identical) tropism as the first virus.

[0070] "AAV (virus) particle", "AAV virion" or "AAV (vector) particle" refers to a virus particle composed of at least one AAV capsid protein and an encapsidated single-stranded nucleic acid chain. In certain embodiments, the AAV particle contains a heterologous nucleic acid sequence (i.e., a nucleic acid other than the wild-type AAV genome, such as a transgene delivered to a eukaryotic cell, such as but not limited to a mammalian cell or an insect cell). In general, the related term "AAV capsid" refers to the outer surface (i.e., capsid) of the AAV particle. The AAV capsid contains 60 copies (in total) of three VPs, which are expected to appear in the capsid in a ratio of VP1:VP2:VP3 of 1:1:10. Therefore, references to "AAV capsid protein" throughout this specification cover each of VP1, VP2 and VP3, or any selection thereof if indicated. It should be understood that where the term "conjugated AAV particles" is used throughout this specification, this means AAV particles that have been subjected to a sortase conjugation reaction.

[0071] "Sortase" and "sortase enzyme" are used interchangeably to refer to a family of enzymes that play a role in bacterial cell wall formation in nature by covalently linking specific surface proteins to peptidoglycan. In the broadest interpretation, a sortase can be defined as an enzyme that recognizes a stretch of amino acids, cleaves a specific site in this stretch of amino acids, and ultimately attaches the substrate moiety immediately C-terminal to the cleavage site to the N-terminal residue of the acceptor moiety via a peptide bond. Another way of saying it is that the sortase recognizes a sortase recognition motif in a substrate protein and performs a transpeptidation reaction. In the first reaction step, the sortase cleaves the peptide bond in the sortase recognition motif, forming an acyl intermediate with the cleaved sortase recognition motif. In the second reaction step, the sortase binds to an acceptor moiety (usually at least one glycine or a stretch of glycine) bearing the sortase acceptor motif and transfers the acyl intermediate. This reaction results in the formation of a new peptide bond between the substrate protein and the acceptor moiety. Alternative terms used interchangeably herein and in the art to refer to a "sortase recognition motif" include "sortase recognition sequence" and "sortase recognition tag."

[0072] Different sortases have been described in the art. Non-limiting examples of the present invention include sortases naturally occurring in Gram-positive enzymes. Preferred sortases include sortase A, sortase B, sortase C, sortase D, sortase E, and sortase F. More specific subfamilies of sortases have been described, which are also encompassed by the term "sortase". It is well within the ability of those skilled in the art to assign the identified sortase to the correct class and / or subfamily based on its sequence or functional characteristics (e.g., transpeptidase activity). When "sortase" is generally referred to throughout this specification, it is clear that all sortase types and subtypes, naturally occurring and artificially engineered, are contemplated unless otherwise indicated.

[0073] The AAV capsid protein as described herein is intended to accommodate the physical connection between the AAV capsid protein and the heteroconjugate (molecule). The term "heterologous" (used interchangeably with the term "exogenous" in the art) refers to a specific part (in the context of the present invention, a conjugate molecule) that is not present in the native, unmodified version of AAV. Therefore, according to the definition of terms generally accepted in the fields of molecular biology and biotechnology, "heteroconjugate" and "heteroconjugate molecule" refer to being present in a host organism that does not naturally contain or express the molecule.

[0074] The inventors unexpectedly discovered that a sortase recognition sequence can be introduced into a specific internal position of the capsid sequence of an AAV particle to enable conjugation of targeting molecules to the AAV capsid (producing conjugated AAV particles), thereby more effectively and specifically targeting tissues and cells than the appropriate parental AAV serotype while maintaining similar production efficiency. This discovery is compelling for the following reasons:

[0075] - For biotechnological applications, there is a general teaching in the art that sortase recognition sequences need to be located at the C-terminus of a protein, or at least near it, to function. The concept that an internally located sortase recognition sequence in an AAV capsid protein is both functional and accessible is surprising.

[0076] - Remarkably, the structural and functional integrity of the (now cleaved) capsid proteins forming the (conjugated) AAV capsids is maintained even after the sortase reaction. Despite the introduction of the extended linker sequence, the AAV capsid proteins remain susceptible to conjugation by the sortase. Furthermore, it was surprisingly found that the insertion of the sortase recognition sequence in combination with a relatively long linker sequence (even exceeding the length of 34 amino acids indicated in the art as the maximum insertion length) in the surface exposed region does not negatively affect the structural or functional properties of the viral capsid proteins.

[0077] - It is not conceivable that the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region can be brought into such a way that the sortase and acceptor moieties can come into close proximity to complete the sortase reaction.

[0078] - Unexpectedly, the inventors' findings can be easily replicated (or extrapolated) in different AAV serotypes. The sequence diversity of AAV capsid proteins in different serotypes does not constitute a barrier to the insertion and use of internal sortase recognition sequences.

[0079] Therefore, the present invention provides an adeno-assisted virus (AAV) capsid protein, characterized in that a sortase recognition sequence is inserted into its protein sequence (particularly VP1, VP2 or VP3 capsid protein). More particularly, the present invention relates to an adeno-associated virus (AAV) capsid protein, characterized in that a sortase recognition sequence is inserted into one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region and the VR-VIII region. Optionally, the AAV capsid protein is VP1, and the sortase recognition sequence is inserted into VP1-VP2, VR-I, VR-IV, VR-VIII or any combination thereof. Preferably, the AAV capsid protein is VP1, and the sortase recognition sequence is inserted into VR-I, VR-IV, VR-VIII or any combination thereof. Alternatively, the AAV capsid protein is VP2, and the sortase recognition sequence is inserted into VR-I, VR-IV, VR-VIII or any combination thereof. Alternatively, the AAV capsid protein is VP3 and the sortase recognition sequence is inserted into VR-I, VR-IV, VR-VIII or any combination thereof. Considering that the sequence of VP3 is completely encompassed by the sequence of VP2, which in turn is completely encompassed by the sequence of VP1, the AAV capsid protein may be a protein comprising the sequence of the VP3 protein as defined herein. Alternatively or additionally, the AAV capsid protein may be a protein comprising the sequence of the VP2 protein as defined herein. However, alternatively or additionally, the AAV capsid protein may be a protein comprising the sequence of the VP3 protein as defined herein. Obviously, in the envisaged aspects, the VP1, VP2 or VP3 sequence differs from the typical sequence of the protein due to the presence of one or more sortase recognition motifs. Therefore, the subject AAV capsid protein of the present invention does not have 100% sequence identity with the naturally occurring VP1, VP2 or VP3 proteins or their coding sequences. Thus, in certain embodiments, the AAV capsid protein comprises an amino acid sequence that is at least about 80% identical, preferably at least about 85% identical, at least about 90% identical, at least about 95% identical, or at least about 98% identical to the amino acid sequence of a naturally occurring (i.e., wild-type) AAV capsid protein, wherein the capsid protein comprises at least one sortase recognition sequence. In preferred embodiments, the AAV capsid protein comprises an amino acid sequence that is at least about 80% identical, preferably at least about 85% identical, at least about 90% identical, at least about 95% identical, or at least about 98% identical to the amino acid sequence of a naturally occurring (i.e., wild-type) AAV2 or AAV9 capsid protein (preferably an AAV2 capsid protein).

[0080] In a preferred embodiment, the sortase recognition sequence is operably linked to an N-terminal linker (i.e., the linker sequence N-terminal to the sortase recognition motif). In an alternative preferred embodiment, the sortase recognition sequence is operably linked to a C-terminal linker (i.e., the linker sequence C-terminal to the sortase recognition motif). In a more preferred embodiment, the sortase recognition sequence is flanked by N-terminal and C-terminal linker sequences. Optionally, the linker sequence is a GGGGS [SEQ ID NO: 39] sequence or any multiple thereof, or a GGSGS [SEQ ID NO: 47] sequence or any multiple thereof. Optionally, the linker sequence comprises a GGGGS [SEQ ID NO: 39] sequence, comprises a GGSGS [SEQ ID NO: 47] sequence, or comprises any combination thereof.

[0081] Obviously, for any of the sortase recognition sequences and optional linker sequences described herein, each of the sequences must be operably linked to the N-terminal and C-terminal portions of the AAV capsid protein. The term "operably linked" is well known to those of ordinary skill in molecular biology and refers to an arrangement of elements in which the components are configured to perform their usual functions. Thus, the sortase recognition sequence is operably linked to an internal position within the AAV capsid protein sequence without interrupting the translation of the AAV capsid protein. As long as the control sequence plays a role in controlling the expression of the coding sequence, the control sequence does not have to be adjacent to the coding sequence.

[0082] Optionally, the sortase recognition sequence is a sequence corresponding to a sortase recognition sequence of a naturally occurring sortase, such as, but not limited to, a naturally occurring sortase in Gram-positive bacteria. Preferably, the sortase recognition sequence is a sequence corresponding to a universal sortase recognition sequence of a sortase selected from the group consisting of sortase A, sortase B, sortase C, sortase D, sortase E, and sortase F. Preferably, the sortase recognition sequence is a sequence corresponding to a universal sortase recognition sequence of sortase A.

[0083] In certain embodiments, the AAV capsid protein comprises two or more sortase recognition sequences of a sortase selected from the group consisting of: sortase A, sortase B, sortase C, sortase D, sortase E, sortase F. Preferably, in embodiments wherein multiple sortase recognition sequences are inserted, the sortase recognition sequences are inserted at different positions of the AAV capsid protein. In such embodiments, the sortase recognition sequence may be the same sortase recognition sequence or any combination of sortase recognition sequences of a sortase selected from the group consisting of: sortase A, sortase B, sortase C, sortase D, sortase E, and sortase F. Preferably, the AAV capsid protein comprises at least one sortase A recognition sequence.

[0084] Optionally, the sortase recognition sequence is a sequence having a universal sequence motif selected from the group consisting of LPXTG [SEQ ID NO: 10], NPXTG [SEQ ID NO: 40], LPXTA [SEQ ID NO: 41], LAXTG [SEQ ID NO: 42], LPXAG [SEQ ID NO: 48], LPXLG [SEQ ID NO: 49], APXTG [SEQ ID NO: 50], LPXSG [SEQ ID NO: 51], FPXTG [SEQ ID NO: 52], XPKTG [SEQ ID NO: 53], and LPEXG [SEQ ID NO: 54], wherein X is any amino acid. Preferably, the sortase recognition sequence is a sequence having the universal sequence motif LPXTG [SEQ ID NO: 10], wherein X is any amino acid and wherein X is independently defined for Xn and Xm. In a further preferred embodiment, the sortase recognition sequence is LPQTG [SEQ ID NO:43], LPETG [SEQ ID NO:44], LPNTG [SEQ ID NO:45], LPDTG [SEQ ID NO:46], NPQTN [SEQ ID NO:55], QVPTG [SEQ ID NO:56], LPNTA [SEQ ID NO:57], LPLTG [SEQ ID NO:58], APKTG [SEQ ID NO:59], DPKTG [SEQ ID NO:60], SPKTG [SEQ ID NO:61], APATG [SEQ ID NO:62], LAETG [SEQ ID NO:63], LPEAG [SEQ ID NO:64], LPECG [SEQ ID NO:65], LPESG [SEQ ID NO:66], or LMVGG [SEQ ID NO:67]. In the most preferred embodiments, the sortase recognition sequence is LPQTG [SEQ ID NO:43] or LPETG [SEQ ID NO:44]. Another suitable way to describe the sortase recognition sequence as described herein is by the format "Xn-sortase recognition sequence-Xm". Thus, the format indicates the optional presence of a linker sequence, wherein "X" represents any amino acid, and "n" and "m" are integers representing the length (i.e., the number of amino acids) of the linker sequence. Obviously, X can be defined independently for Xn and Xm. Thus, in certain embodiments, the sortase recognition sequence is immediately after the sequence Xn and immediately before the sequence Xm.Thus, the sortase recognition sequences described herein can alternatively be represented by: Xn-LPXTG-Xm [SEQ ID NO:10], Xn-NPXTG-Xm [SEQ ID NO:40], Xn-LPXTA-Xm [SEQ ID NO:40], Xn-LAXTG-Xm [SEQ ID NO:42], Xn-LPXAG-Xm [SEQ ID NO:48], Xn-LPXLG-Xm [SEQ ID NO:49], Xn-APXTG-Xm [SEQ ID NO:50], Xn-LPXSG-Xm [SEQ ID NO:51], Xn-FPXTG-Xm [SEQ ID NO:52], Xn-XPKTG-Xm, [SEQ ID NO:53], and Xn-LPEXG-Xm, [SEQ ID NO:54], wherein X is any amino acid and n and m range from 0 to 25. Preferably, the sortase recognition sequence is a sequence having the general sequence motif Xn-LPXTG-Xm [SEQ ID NO: 10], wherein X is any amino acid and n and m range from 0 to 25. More preferably, the sortase recognition sequence is Xn-LPQTG-Xm [SEQ ID NO:43], Xn-LPETG-Xm [SEQ ID NO:44], Xn-LPNTG-Xm [SEQ ID NO:45], Xn-LPDTG-Xm [SEQ ID NO:46], Xn-NPQTN-Xm [SEQ ID NO:55], Xn-QVPTG-Xm [SEQ ID NO:56], Xn-LPNTA-Xm [SEQ ID NO:57], Xn-LPLTG-Xm [SEQ ID NO:58], Xn-APKTG-Xm [SEQ ID NO:59], Xn-DPKTG-Xm [SEQ ID NO:60], Xn-SPKTG-Xm [SEQ ID NO:61], Xn-APATG-Xm [SEQ ID NO:62], Xn-LAETG-Xm [SEQ ID NO:63], NO:63], Xn-LPEAG-Xm[SEQ ID NO:64], Xn-LPECG-Xm[SEQ ID NO:65], Xn-LPESG-Xm[SEQ ID NO:66], or Xn-LMVGG-Xm[SEQ ID NO:67]. Most preferably, the sortase recognition sequence is Xn-LPQTG-Xm[SEQ ID NO:43] or Xn-LPETG-Xm[SEQ ID NO:44].

[0085] As described above, in certain embodiments, the sortase recognition sequence precedes and / or follows the linker sequence (i.e., embodiments in which the sortase recognition sequence precedes or follows the Xn and / or Xm sequence, wherein n and / or m is at least 1, and wherein X for Xn and Xm can be defined independently of each other). Thus, the present invention contemplates embodiments in which n and / or m is 0, but also contemplates embodiments in which n and / or m is at least 1. Thus, in certain embodiments, n and / or m is an integer from 0 to 25, such as at least 2, at least 3, at least 4, or at least 5, preferably from 5 to 20, such as from 10 to 15.

[0086] Optionally, n and / or m is an integer from 15 to 20, or an integer between 15 and 20. Optionally, n and / or m is an integer from 10 to 15, or an integer between 10 and 15. Optionally, n and / or m is an integer from 5 to 10, or an integer between 0 and 5. Optionally, n and / or m is 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0. Further contemplated embodiments wherein n is 0 and m is an integer from 0 to 25, preferably from 0 to 20. Also contemplated embodiments wherein m is 0 and n is an integer from 0 to 25, preferably from 0 to 20.

[0087] The exact sequence of the joint sequence Xn and Xm is not particularly limited for the present invention. However, preferred Xn and Xm sequences (or their characteristics) will be described in the following paragraphs. Preferably, the joint sequence Xn, Xm or Xn and Xm are both composed of at least 65%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 85%, more preferably at least 90%, more preferably at least 95% glycine, serine, threonine and alanine. More preferably, the joint sequence Xn, Xm or Xn and Xm are both composed of glycine, serine, threonine and alanine. Alternatively, the joint sequence Xn, Xm or Xn and Xm are both composed of at least 65%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 85%, more preferably at least 90%, more preferably at least 95% glycine and serine. In further alternative embodiments, the joint sequence Xn, Xm or Xn and Xm are both composed of glycine and serine. In a specific embodiment, the linker sequence is GGSGS [SEQ ID NO: 47].

[0088] Each of the regions described herein in which a sortase recognition sequence may be inserted has been described on numerous occasions throughout the art, and thus a person of ordinary skill in the art is fully capable of identifying these regions. Optionally, the VP1-VP2 transition region is defined by SEQ ID NO: 1 [PVKTAP]. Optionally, the VR-I region is defined by SEQ ID NO: 2 [SSQSGASN]. Optionally, the VR-IV region is defined by SEQ ID NO: 3 [SRTNTPSGTTTQSRLQFSQAGASDIRDQS]. Optionally, the VR-VIII region is defined by SEQ ID NO: 4 [QYGSVSTNLQRGNRQAATADVNTQGV]. In a preferred embodiment, the VR-I region is defined by SEQ ID NO: 2 [SSQSGASN], the VR-IV region is defined by SEQ ID NO: 3 [SRTNTPSGTTTQSRLQFSQAGASDIRDQS], and the VR-VIII region is defined by SEQ ID NO: 4 [QYGSVSTNLQRGNRQAATADVNTQGV]. In a further preferred embodiment, the VP1-VP2 transition region is defined by SEQ ID NO: 1 [PVKTAP], the VR-I region is defined by SEQ ID NO: 2 [SSQSGASN], the VR-IV region is defined by SEQ ID NO: 3 [SRTNTPSGTTTQSRLQFSQAGASDIRDQS], and the VR-VIII region is defined by SEQ ID NO: 4 [QYGSVSTNLQRGNRQAATADVNTQGV]. It will be appreciated that SEQ ID NO: 1 to SEQ ID NO: 4 correspond to sequences into which no sortase recognition motif has been inserted, i.e. sequences that the inventors have found to be capable of accepting one or more sortase recognition motifs, optionally flanked by one or more linkers. Also envisaged are corresponding amino acid sequences in AAV serotypes other than AAV2.

[0089] In embodiments where the sortase recognition sequence is inserted into the VR-IV region, the sortase recognition sequence may preferably be inserted into a fragment having SEQ ID NO:5 [TPSGTTTQS] and / or in the VR-VIII region into a fragment having SEQ ID NO:6 [LQRGNRQAA]. In such embodiments, the sortase recognition sequence may be inserted after the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, or 9th amino acid of SEQ ID NO:5. In alternative such embodiments, the sortase recognition sequence may be inserted after the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, or 9th amino acid of SEQ ID NO:6. In alternative embodiments, the first sortase recognition sequence may be inserted after the 1st, 2nd, 3rd, 4th, 5th, 7th, 8th, or 9th amino acid of SEQ ID NO:5 and the second sortase recognition sequence may be inserted after the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, or 9th amino acid of SEQ ID NO:6.

[0090] The sortase recognition sequences described herein can be inserted into the VP1-VP2 transition region, VR-I region, VR-IV region and / or VR-VIII region by inserting one or more sortase recognition sequences into the genomic sequence of one or more regions. The insertion may be an insertion without removing the canonical amino acids in the one or more regions. In the embodiments, the sortase recognition sequence is introduced in addition to the original sequence. Alternatively, the sortase recognition sequences described herein can be inserted into the VP1-VP2 transition region, VR-I region, VR-IV region and / or VR-VIII region by inserting and deleting (resulting in substitution or replacement) the sortase recognition sequence into the genomic sequence of one or more regions. The deletion or substitution may correspond to any number of amino acids in the VP1-VP2 transition region, VR-I region, VR-IV region and / or VR-VIII region, as long as the structural integrity of the region (and the AAV capsid protein obtained therefrom) is maintained. In some embodiments, the functional integrity of the AAV protein may be affected because the insertion site interferes with a specific function (e.g., the HSPG binding site of VR-VIII in AAV2), although these are not critical to the further use of the conjugated protein. However, in further embodiments, both the structural and functional integrity of the region (and thereby the resulting AAV capsid protein) are maintained.

[0091] Without being bound by theory, the inventors note that surface exposed lysines can optionally reduce the efficiency of the sortase-mediated transpeptidation reaction by allowing the generation of unacceptable byproducts. Therefore, in an embodiment of the invention, one or more surface exposed lysines are mutated to, for example, glycine, serine or alanine. The selection of the targeted lysine is based on the distance of the lysine from the loop where the insertion site, such as the LPXTG tag, is added.

[0092] For AAV serotypes other than AAV2, the skilled artisan will be able to identify amino acids corresponding to those disclosed herein.

[0093] Typically, lysine mutations located in close proximity to the region or regions where the sortase recognition sequence is inserted are envisioned.

[0094] Illustratively, 30 angstroms near the VR-I region of AAV2 The lysine at 30 angstroms corresponds to K258, K321, K490, K507, K527, K532, K544, K549, K556, K620, K640, K649, K665, K692, and K706; the lysine at 30 angstroms near the VR-IV region of AAV2 corresponds to K258, K309, K313, K321, K490, K507, K527 , K532, K544, K549, K556, K620, K640, K649, K665, K688, K692 and K706; the lysine at 30 near the VR-VIII region of AAV2 corresponds to K309, K490, K507, K527, K532, K544, K549, K556, K620, K640, K688 and K706.

[0095] Illustratively, the lysines within 15 angstroms near the VR-I region of AAV2 correspond to K258, K507, K527, K549, and K706; the lysines within 15 angstroms near the VR-IV region of AAV2 correspond to K258, K490, K507, K532, K544, K549, K556, and K665; and the lysines within 15 angstroms near the VR-VIII region correspond to K490, K507, K527, and K532.

[0096] Illustratively, the lysine 5 angstroms near the VR-IV region of AAV2 is K549; the lysine 5 angstroms near the VR-VIII region of AAV2 is K507.

[0097] Optionally, a sortase recognition sequence is inserted into the VR-I region and one or more of the lysines at positions K258, K321, K490, K507, K527, K532, K544, K549, K556, K620, K640, K649, K665, K692, K706 in AAV2, or the corresponding amino acids in another serotype are mutated. In a preferred embodiment, a sortase recognition sequence is inserted into the VR-I region and one or more of the lysines at positions K258, K507, K527, K549 and K706 in AAV2, or the corresponding amino acids in another serotype are mutated. Optionally, a sortase A recognition sequence is inserted into the VR-I region and one or more lysines at positions K258, K321, K490, K507, K527, K532, K544, K549, K556, K620, K640, K649, K665, K692, K706 in AAV2 or the corresponding amino acids in another serotype are mutated. Optionally, the sortase A recognition sequence is Xn-LPXTG-Xm [SEQ ID NO: 10].

[0098] Optionally, in embodiments contemplated by the invention, a sortase recognition sequence is inserted into the VR-IV region and one or more of the lysines at positions K258, K309, K313, K321, K490, K507, K527, K532, K544, K549, K556, K620, K640, K649, K665, K688, K692 and K706 in AAV2 or the corresponding amino acids in another serotype are mutated. In a preferred embodiment, a sortase recognition sequence is inserted into VR-IV and one or more of the lysines at positions K258, K490, K507, K532, K544, K549, K556 and K665 in AAV2 or the corresponding amino acids in another serotype are mutated. Optionally, the sortase A recognition sequence is inserted into the VR-IV region and one or more of the lysines at positions K258, K309, K313, K321, K490, K507, K527, K532, K544, K549, K556, K620, K640, K649, K665, K688, K692 and K706 in AAV2 or the corresponding amino acid in another serotype are mutated. Optionally, the sortase A recognition sequence is Xn-LPXTG-Xm [SEQ ID NO: 10]. In a further preferred embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into the VR-IV region and the lysine at position K549 in AAV2 or the corresponding amino acid in another serotype is mutated, preferably to glycine or alanine.

[0099] Optionally, a sortase recognition sequence is inserted into the VR-VIII region and one or more of the lysines at positions K309, K490, K507, K527, K532, K544, K549, K556, K620, K640, K688 and K706 in AAV2 or the corresponding amino acids in another serotype are mutated. In a preferred embodiment, a sortase recognition sequence is inserted into the VR-VIII region and one or more of the lysines at positions K490, K507, K527 and K532 in AAV2 or the corresponding amino acids in another serotype are mutated. Optionally, a sortase A recognition sequence is inserted into the VR-VIII region and one or more of the lysines at positions K309, K490, K507, K527, K532, K544, K549, K556, K620, K640, K688 and K706 in AAV2 or the corresponding amino acids in another serotype are mutated. Optionally, the sortase A recognition sequence is Xn-LPXTG-Xm [SEQ ID NO: 10].

[0100] In a further preferred embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into region VR-VIII and the lysine at position K507 or the corresponding amino acid in another serotype is mutated, preferably to glycine or alanine.

[0101] A further aspect of the present invention relates to a nucleic acid (i.e., a nucleic acid sequence) encoding any of the AAV capsid proteins described herein and its use in a method for preparing AAV particles. Therefore, it encompasses a nucleic acid sequence encoding any of the AAV capsid proteins described herein, the AAV capsid protein having a sortase recognition sequence in one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region, and the VR-V-VIII region. The nucleic acid can be DNA, RNA, a variant, or any combination of DNA and RNA. The construction method of the nucleic acid construct disclosed herein is well known. The nucleic acid can be a nucleic acid further comprising a promoter sequence. The term "promoter" as defined herein is a DNA region that initiates transcription of a specific gene and thus enables the gene to be transcribed. The promoter is recognized by RNA polymerase and then initiates transcription. Therefore, the promoter comprises a DNA sequence that directly binds to RNA polymerase or participates in the recruitment of RNA polymerase. The promoter sequence may also include an "enhancer region", which is one or more regions of DNA that can bind to proteins (i.e., trans-acting factors) to enhance the transcription level of genes in a gene cluster. Although enhancers are usually located 5' to the coding region, they can also be separated from the promoter sequence, for example, enhancers can be located in the intron region of the gene or 3' to the coding region of the gene. The promoter can be located near the start codon of the gene, in the preferred embodiment on the same strand and usually upstream (5') of the gene. The size of the promoter can vary, preferably about 100 to 1000 nucleotides long.

[0102] Therefore, the term nucleic acid encompasses (recombinant) nucleic acid vectors and (recombinant) nucleic acid expression vectors, which is another aspect of the present invention. It is known to technicians that nucleic acid (expression) vectors are suitable for transporting nucleic acids of the present invention to cells in an environment, such as, but not limited to, organisms, tissues, or cell cultures. The vector can be used to prepare, for example, an open reading frame encoding the subject AAV capsid protein of the present invention. In the embodiment, the subject AAV capsid protein of the present invention can be expressed by nucleic acid under in vitro or in vivo conditions (that is, the nucleic acid encodes at least the amino acid sequence of the AAV capsid protein). Therefore, the nucleic acids described herein may be suitable for preparing or assisting in the preparation of AAV particles and finally conjugated AAV particles, and the (optionally conjugated) AAV particles are further described in detail throughout this specification. A recombinant expression vector refers to a nucleic acid encoding a protein, wherein the nucleic acid can express the encoded protein, which is an AAV capsid protein in the context of the present invention. Examples of the vector include plasmids, nucleic acid viral vectors, and viral genomes (including DNA and RNA genomes). Therefore, the present disclosure contemplates a recombinant AAV vector.

[0103] The term "recombinant AAV vector" is used interchangeably with terms such as "recombinant AAV", "recombinant AAV virus" and "recombinant AAV virus particle", indicating that the genomic DNA encapsulated in the AAV virus capsid contains a heterologous nucleic acid. In the recombinant AAV vector of the present invention, at least the AAV capsid protein is replaced by a heterologous nucleic acid comprising an AAV capsid protein, wherein the AAV capsid protein is characterized by a sortase recognition sequence in one or more of the VP1-VP2 transition region, VR-I region, VR-IV region and / or VR-VIII region. The coding sequences and elements contained in the vector can be expressed in a suitable host cell by any suitable method for introducing the vector into the interior of the cell. Suitable methods include, by way of illustration and without limitation, infection, transformation, transduction and transfection. In addition to the therapeutic gene and / or reporter gene (i.e., the "payload" intended to be delivered to the target cell), the vector may contain multiple components (i.e., elements, features) with expression regulation functions, including but not limited to promoter sequences, transcription start sequences, enhancer sequences, introns, kozak sequences, polyA sequences, selection elements or replication origins.

[0104] In certain embodiments, the nucleic acid comprises a sequence encoding an AAV capsid protein having an amino acid sequence that is at least about 80% identical, preferably at least about 85% identical, at least about 90% identical, at least about 95% identical, or at least about 98% identical to the amino acid sequence of a naturally occurring (i.e., wild-type) AAV capsid protein, wherein the capsid protein comprises at least one sortase recognition sequence. In a preferred embodiment, the nucleic acid comprises a sequence encoding an AAV capsid protein having an amino acid sequence that is at least about 80% identical, preferably at least about 85% identical, at least about 90% identical, at least about 95% identical, or at least about 98% identical to the amino acid sequence of a naturally occurring (i.e., wild-type) AAV2 or AAV9 capsid protein (preferably an AAV2 capsid protein).

[0105] The present invention aims to provide a robust and efficient means for coupling heterologous conjugate molecules to AAV particles (producing conjugated AAV particles), in particular to AAV capsid proteins. Therefore, another aspect of the present invention relates to AAV particles, which contain a sortase recognition sequence located in one or more of the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region of the AAV capsid protein. The skilled person understands that after performing the sortase conjugation reaction, the sortase recognition sequence will be modified because the C-terminal glycine residue is "cleaved" and the remaining part of the sortase recognition sequence is attached to a different glycine from the conjugated molecule. Therefore, the skilled person understands that although two AAV particles are envisioned as the starting material for conjugation (i.e., the "input" material), the AAV particles obtained by performing the sortase conjugation reaction (i.e., the "output" material; conjugated AAV particles) are likewise envisioned. Generally, in the present disclosure, the sortase recognition sequence portion of the AAV capsid protein after the sortase conjugation reaction is denoted as a "modified sortase recognition sequence", or a "residual sortase recognition sequence". It is therefore understood that the residual sortase recognition sequence described herein is a sequence that physically links the conjugated AAV capsid protein to a heterologous conjugation molecule, and preferably operably links the conjugated AAV capsid protein to a heterologous conjugation molecule, such as, but not limited to, the conjugation molecules further described below.

[0106] In other words, the present invention thus provides AAV particles comprising a genomic modified AAV capsid protein, wherein the genomic modification is the presence of a sortase recognition sequence in one or more of the VP1-VP2 transition region, VR-I region, VR-IV region, and / or VR-VIII region. Thus, genomic modifications are contemplated for any AAV particle in which the AAV capsid protein does not have a sortase recognition sequence in one or more of the VP1-VP2 transition region, VR-I region, VR-IV region, and / or VR-VIII region.

[0107] Thus, in certain embodiments, the AAV particles comprise an AAV capsid protein characterized by the presence of a sortase recognition sequence in one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region, and / or the VR-V-VIII region. In alternative embodiments, the conjugated AAV particles comprise an AAV capsid protein characterized by the presence of a residual sortase recognition sequence in one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region, and / or the VR-V-VIII region that is operably linked to a heterologous conjugated molecule. Taking into account the internal location of the sortase recognition sequence and the details of the sortase conjugation reaction, the AAV capsid protein (which may be a VP1, VP2, or VP3 protein) after the conjugation reaction will effectively exist in the AAV capsid as two separate proteins: a first N-terminal protein containing the N-terminal end of the VP portion containing the residual sortase recognition sequence, the residual sortase recognition sequence, and the conjugated molecule; and a second C-terminal protein containing the C-terminal end of the VP portion containing the (initial) sortase recognition sequence. The sortase recognition sequence is inserted into the AAV capsid protein sequence to allow the two parts to maintain structural integrity after the conjugation reaction.

[0108] With respect to conjugated AAV particles, the inventors further unexpectedly observed that conjugated AAV particles to which a relatively low portion of AAV capsid protein was conjugated exhibited a more significant improvement in transduction efficiency than conjugated AAV particles to which a relatively high portion of AAV capsid protein was conjugated. Apparently, the lower amount of conjugated AAV capsid protein in the conjugated AAV particles may be due to a lower amount of AAV capsid protein containing a sortase recognition sequence, or to (optionally intentionally) suboptimal parameters for conducting the conjugation reaction. The present invention contemplates two embodiments.

[0109] Therefore, optionally, the ratio of the capsid protein that is not conjugated (i.e., unmodified capsid protein or unconjugated capsid protein) to the conjugated capsid protein (i.e., modified capsid protein) in the conjugated AAV particles is between about 1 / 59 and about 59 / 1, preferably between about 1 / 20 and about 20 / 1, preferably between about 1 / 15 and about 15 / 1, preferably between about 1 / 10 and about 10 / 1, more preferably between about 1 / 9 and about 9 / 1, more preferably between about 1 / 8 and about 8 / 1, more preferably between about 1 / 7 and about 7 / 1, more preferably between about 1 / 6 and about 6 / 1, more preferably between about 1 / 5 and about 5 / 1. In a more preferred embodiment, the ratio of the capsid protein that is not conjugated (i.e., unmodified capsid protein) to the conjugated capsid protein (i.e., modified capsid protein) in the conjugated AAV particles is less than about 1 / 5, preferably less than about 1 / 10, preferably less than about 1 / 15, preferably less than about 1 / 20. In a preferred embodiment, the conjugated AAV particles contain at least 1 conjugated capsid protein (i.e., up to 59 non-conjugated capsid proteins). In a preferred embodiment, the conjugated AAV particles contain 1 to 20 conjugated capsid proteins, preferably 1 to 15 conjugated capsid proteins, preferably 1 to 10 conjugated capsid proteins, and more preferably 1 to 5 conjugated capsid proteins. In a specific embodiment, the conjugated AAV particles contain 1 conjugated capsid protein. Preferably, the conjugated AAV particles contain at least 5% conjugated AAV capsid proteins. On the other hand, the inventors have found that, where necessary, the present invention allows for effective conjugation of capsid proteins, which is of great significance. Therefore, in a specific embodiment, the conjugated AAV particles contain at least 20, preferably at least 30, more preferably at least 40, for example at least 50 conjugated capsid proteins.

[0110] It is generally assumed that each AAV particle will contain at least one VP1 and at least one VP2, in a theoretical ratio of VP1:2:3 or 5:5:50. It will therefore be appreciated that by introducing a sortase recognition sequence into one or more regions of the capsid protein, the amount of conjugated protein in the particle can be influenced.

[0111] Optionally, the VP1, VP2 or VP3 proteins in the (optionally conjugated) AAV particles (the VP1, VP2 or VP3 proteins comprising a sortase recognition sequence in one or more of the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region) have the same amino acid sequence (i.e., there are no VP1 capsid proteins with sequences that differ from each other in a single assembled AAV particle, there are no VP2 capsid proteins with sequences that differ from each other in a single assembled AAV particle, and / or there are no VP3 capsid proteins with sequences that differ from each other in a single assembled AAV particle). In such embodiments, the sortase recognition sequences may be different, and / or one or more sortase recognition sequences may be inserted into different regions of the AAV capsid protein.

[0112] The details of the heteroconjugate molecule are not particularly limited to the present invention, provided that the details are acceptable for sortase-mediated conjugation molecules. Typically, this requires the presence of an N-terminal triglycine sequence (i.e., GGG). By way of illustration and not limitation, suitable heteroconjugate molecules may be small molecules, carbohydrates, lipids, or proteins.

[0113] In a preferred embodiment, the heteroconjugate molecule is a targeting moiety. As used herein, the term "targeting moiety" encompasses any molecule that can bind to a specific tissue, cell type and / or organ over other tissues, targets and / or organs, respectively. The details of the targeting moiety are not particularly restrictive for the present invention, and therefore include, by way of illustration and without limitation, ligands of cell receptors and proteins that bind to cell surface proteins. Therefore, preferred heteroconjugate molecules include antibodies and antibody fragments, such as, but not limited to, nanobodies. Optionally, in embodiments in which the heteroconjugate molecule is an antibody or an antibody fragment, such as an antibody, the heteroconjugate molecule specifically binds to human epidermal growth factor receptor 2 (HER2).

[0114] Related aspects of the invention relate to conjugated AAV particles as described herein for use as a medicament. Thus, the invention encompasses a method for treating a subject in need thereof, the method comprising the step of administering the conjugated AAV particles to the subject. It is also contemplated that the conjugated AAV particles described herein are used for the preparation of a medicament. Specific medical conditions for which the present invention is intended include proliferative diseases (i.e., cancer) and tissue-specific diseases (e.g., liver disease). Obviously, the products described herein related to the conjugated AAV particles (e.g., AAV capsid proteins described herein, nucleic acids described herein, and nucleic acid vectors described herein) can also be used for medical purposes.

[0115] The terms "subject", "patient" and "subject in need" are used interchangeably and refer to animals, preferably warm-blooded animals, more preferably vertebrates, and even more preferably mammals, specifically including humans and non-human mammals. The term "mammal" or "mammalian subject" refers to any animal classified as such, thus including but not limited to humans, domestic animals, commercial animals, farm animals, zoo animals, sports animals, pets and experimental animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows; primates, such as apes, monkeys, gorillas and chimpanzees; canines, such as dogs and wolves; felines, such as cats, lions and tigers; equines, such as horses, donkeys and zebras; food animals, such as cattle, pigs and sheep; ungulates, such as deer and giraffes; rodents, such as mice, rats, hamsters and guinea pigs; and the like. Preferred patients are human subjects. Particularly preferred are human subjects of both sexes and all age categories thereof.

[0116] A related aspect of the invention relates to a method for preparing conjugated AAV particles, comprising expressing in a cell a nucleic acid encoding a capsid protein as described herein, allowing the cell to form AAV particles, recovering the AAV particles and conjugating these AAV particles to a molecule of interest. In a specific embodiment, the method comprises the following steps:

[0117] - contacting the cell with one or more nucleic acids encoding an AAV capsid protein, wherein one or more of the VP1-VP2 transition region, VR-I region, VR-IV region, or VR-VIII region of the AAV capsid protein comprises a sortase recognition sequence;

[0118] - allowing the cells to assemble multiple AAV capsid proteins into AAV particles and collecting the AAV particles from the cells; and

[0119] - Contacting the sortase and the heterologous conjugate molecule with the AAV particles.

[0120] The skilled person understands that between the step of providing the cells with one or more nucleic acids encoding a plurality of AAV capsid proteins and the step of collecting the AAV particles, a step of culturing the cells occurs to allow transcription and translation of the AAV capsid proteins and assembly into AAV particles. Optionally, the one or more nucleic acid sequences described in the method correspond to three nucleic acid sequences: a first nucleic acid encoding the rep and cap genes, a second nucleic acid comprising a transgene and an ITR region, and a third nucleic acid encoding any auxiliary proteins for assembling AAV particles. In certain embodiments, the step of collecting the AAV particles is preceded by a step of lysing the cells contained in the cell culture. Methods for preparing AAV particles have been described on many occasions in the art and are therefore known to the skilled person.

[0121] In a preferred embodiment, the sortase recognition sequence is a sortase A recognition sequence, more preferably the sequence Xn-LPXTG-Xm [SEQ ID NO: 10].

[0122] In preferred embodiments, the AAV capsid protein comprises a sortase recognition sequence in one or more of the VR-I region, the VR-IV region, or the VR-V-VIII region.

[0123] Optionally, the method further comprises an additional step of enriching, purifying and / or isolating the assembled AAV particles prior to contacting the AAV particles with the sortase and the heterologous conjugate molecule. As an alternative and / or supplement to the above embodiment, the method further comprises a step of depleting or removing AAV capsid proteins that are not part of the assembled AAV particles prior to contacting the AAV particles with the sortase and the heterologous conjugate molecule.

[0124] In certain embodiments, in the conjugation step of the methods contemplated herein, the AAV capsid protein, the sortase, and the heteroconjugate molecule are provided in a ratio of 1:1:1. In alternative embodiments, an excess of the sortase and the heteroconjugate molecule are provided to maintain a 1:>1:>1 ratio of the molecules. In further embodiments, an excess of the heteroconjugate molecule is provided to maintain a 1:1:>1 ratio, preferably a 1:1:>5 ratio, more preferably a 1:1>10 ratio. In a preferred embodiment, the AAV capsid protein, the sortase, and the heteroconjugate molecule are provided in a ratio of about 1:0.1:1.

[0125] Optionally, after contacting the AAV particles with the sortase and the heterologous conjugated molecule, the method comprises a further step of enriching, purifying and / or isolating assembled conjugated AAV particles containing at least one conjugated AAC capsid protein. In a further embodiment, the method comprises a further step of enriching, purifying and / or isolating assembled conjugated AAV particles, wherein the assembled conjugated AAV particles contain at least 10%, preferably at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90% or even 100% conjugated AAV capsid protein.

[0126] Optionally, the AAV capsid protein comprises a plurality of different sortase recognition sequences, and the AAV particles are contacted with different sortases and conjugated molecules in a sequential manner. A plurality of different sortase recognition sequences may be provided in a single AAV capsid protein, or alternatively may be provided by using a collection of AAV capsid proteins each comprising a different sortase recognition sequence, optionally at different positions in the AAV capsid protein. Preferably, an AAV capsid protein is provided, the capsid protein containing a sortase recognition sequence in one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region, or the VR-V-VIII region. In a specific embodiment, a combination of a naturally occurring AAV capsid protein and an AAV capsid protein containing a sortase recognition sequence in one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region, and the VR-V-VIII region is provided.

[0127] Obviously, any embodiment described herein regarding AAV capsid proteins is equally applicable to (isolated) AAV capsid proteins, but also equally applicable to AAV capsid proteins encoded by nucleic acids or nucleic acid vectors and (assembled) AAV particles, and vice versa.

[0128] In addition to the above embodiments, the present invention also relates to an adeno-associated virus (AAV) VP1, VP2 or VP3 capsid protein, wherein the adeno-associated virus (AAV) VP1, VP2 or VP3 capsid protein is characterized in that a sortase recognition sequence Xn-LPXTG-Xm [SEQ ID NO: 10] is inserted into one or more of the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region, wherein n and m range from 0 to 20, and wherein X is any natural amino acid. In a specific embodiment, the adeno-associated virus (AAV) VP1, VP2 or VP3 capsid protein is characterized by the insertion of a sortase recognition sequence Xn-LPXTG-Xm (SEQ ID NO: 10) in one or more of the VP1-VP2 transition region, VR-I region, VR-IV region and VR-VIII region, wherein n and m range from 0 to 20, wherein X is any natural amino acid, wherein the VP1-VP2 transition region is defined by SEQ ID NO: 1 [PVKTAP], the VR-I region is defined by SEQ ID NO: 2 [SSQSGASN], the VR-IV region is defined by SEQ ID NO: 3 [SRTNTPSGTTTQSRLQFSQAGASDIRDQS], and the VR-VIII region is defined by SEQ ID NO: 4 [QYGSVSTNLQRGNRQAATADVNTQGV]. In specific embodiments, the insertion in the VR-IV region is located in a fragment having SEQ ID NO: 5 [TPSGTTTQS] and / or in a fragment having SEQ ID NO: 6 [LQRGNRQAA]. In specific embodiments, one or more amino acids in the region where the sortase recognition site is inserted are deleted. In specific embodiments of any of the above embodiments, the AAV is AAV2 or AAV9. In further specific embodiments of any of the above embodiments, n is between 15 and 20, between 10 and 15, between 5 and 10, or between 0 or 5, or is 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1. In particular, it is envisaged that m is between 15 and 20, between 10 and 15, between 5 and 10, between 0 or 5, or is 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acids. In specific embodiments of any of the above embodiments, the linker sequence Xn or Xm comprises at least 80% Gly, Ser, Thr and Ala. Preferably, the linker sequence Xm or Xn consists of an amino acid selected from the group consisting of Gly, Ser, Thr and Ala. In a specific embodiment of any of the above embodiments, LPXTG is Asp, Glu, Ans or Gln, typically Gln.In a specific embodiment of any of the above embodiments, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into the VR-1 region and one or more of the lysines at positions K258, K321, K490, K507, K527, K532, K544, K549, K556, K620, K640, K649, K665, K692, K706 are mutated. In a further specific embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into the VR-1 region and one or more of the lysines at positions K258, K507, K527, K549 and K706 are mutated. In a further specific embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into the VR-IV region, and wherein one or more of the lysines at positions K258, K309, K313, K321, K490, K507, K527, K532, K544, K549, K556, K620, K640, K649, K665, K688, K692, and K706 are mutated. In a further specific embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into VR-IV, and wherein one or more of the lysines at positions K258, K490, K507, K532, K544, K549, K556, and K665 are mutated. In a further specific embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into VR-IV, and wherein the lysine at position K549 is mutated. In a further specific embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into the VR-VIII region, and wherein one or more of the lysines at positions K309, K490, K507, K527, K532, K544, K549, K556, K620, K640, K688 and K706 are mutated. In a further specific embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into VR-VIII, and wherein one or more of the lysines at positions K490, K507, K527 and K532 are mutated. In a further specific embodiment, the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted into VR-VIII, and one or more of the lysines at position K507 are mutated to Gly or Ala. In a preferred embodiment of the embodiments described herein, the one or more lysines are mutated to Gly, Ser or Ala. The present invention also provides nucleic acids encoding the capsid proteins of any of the embodiments described above. The present invention further provides expression vectors comprising these nucleic acids.The present invention further provides AAV particles comprising AAV capsid proteins as described above. In specific embodiments, the ratio of unmodified AAV proteins to modified proteins is between 1 / 20, 1 / 10 or 1 / 5 and 5 / 1, 10 / 1 or 20 / 1. In specific embodiments, AAV particles are fused to conjugates such as small molecules, carbohydrates, and polypeptides through sortase recognition sites. In further specific embodiments, AAV particles are fused to targeting moieties through sortase recognition sites, and the targeting moieties are, for example, ligands of cell receptors or proteins that bind to cell surface proteins. In further specific embodiments, the protein that binds to cell surface proteins is an antibody or nanobody, such as an antibody or nanobody that binds to HER2. The present invention further provides uses of AAV particles as described herein, such as AAV particles as described herein for use as drugs.

[0129] Although the present invention has been described in conjunction with specific embodiments thereof, it is apparent that many alternatives, modifications and variations will be apparent to those skilled in the art from the foregoing description. Therefore, it is intended to cover all such alternatives, modifications and variations as follows within the spirit and broad scope of the appended claims. The aspects, statements and embodiments of the present invention disclosed herein are further supported by the following non-limiting examples. Example

[0130] Example 1: General Design Information, Considerations, and Exploratory Results

[0131] Adeno-associated virus (AAV) is a small, non-pathogenic, non-enveloped ssDNA virus. Its genome (4.7kb) consists of two major open reading frames. The rep gene encodes four replication proteins: the cap gene encodes the three structural proteins of the AAV capsid (VP1, VP2 and VP3), which are formed by alternative splicing and alternative start codons. It forms a 60-subunit capsid in a ratio of 1:1:10. The rep and cap genes are flanked by inverted terminal repeats (ITRs), which are the only genetic elements required for viral DNA replication and packaging. Therefore, the viral rep and cap genes can be provided in trans during the preparation process, and the target transgene of approximately 4.5kb can be inserted between the ITRs to produce a recombinant AAV (rAAV) viral vector ( Figure 1 A).

[0132] In general, sortase reactions have been described in numerous examples throughout the art and are therefore known to those of ordinary skill in the art. The general overview of the sortase A reaction is described as follows: Figure 1B. This results in efficient and controllable antibody-drug conjugation with a uniform and predictable drug to antibody ratio. This technology has not been used so far for enzymatic coupling of targeting moieties to AAV vectors.

[0133] The potential of targeting AAV vectors depends on the targeting potential of the ligand. Nanobodies are a preferred part for this situation. They combine a small and compact structure, high specificity, high stability and low immunogenicity, and the sortase A technology has been widely used in the conjugation of nanobodies to drugs or other nanobodies. In addition, nanobodies can be designed for almost any cell receptor. The present invention is illustrated by the anti-HER2 (human epidermal growth factor receptor 2) nanobody 2Rs15d for radionuclide therapy of breast cancer.

[0134] The sortase A LPXTG recognition motif [SEQ ID NO: 10] can function as part of an exposed loop of the target protein. Previous literature has shown that peptide insertions of up to 34 amino acids into variable regions (VRs) IV-IV and VR-VIII of the AAV capsid are well tolerated. The LPXTG recognition motif [SEQ ID NO: 10] was placed in VR-IIV and VR-VIII as shown in Figure ( Figure 2 The LPXTG [SEQ ID NO: 10] binding cleft on the sortase A enzyme is a fairly deep binding pocket, so the length and sequence of the LPXTG [SEQ ID NO: 10] flanking linkers were considered.

[0135] AAV2-HB0 was used in the present examples, and its ability to bind to the heparan sulfate proteoglycan receptor has been disrupted by mutations (R585A and R588A) to inhibit the natural tropism of AAV2. However, it is clear that the mutations in this particular AAV2 mutant are not limited to the context of the present invention, and the findings described herein are readily applicable to other AAV serotypes and other AAV2 variants in general.

[0136] The sortase A-mediated coupling reaction is performed by Ab recognition (eg HA or FLAG) and affinity tag (eg His) tagged Nanobody-protein. Recombinant 2Rs15d Nanobody was used in this example.

[0137] Different constructs were tested in experiments to assess ligand binding using sortase A. As shown in Table 1, the LPQTG motif [SEQ ID NO: 43] with an optional linker was inserted.

[0138] Table 1 Sequence information about the insertion sites tested.

[0139]

[0140] Nanobodies are usually tagged with a Gly5 tag at the N-terminus and fused to 3xFLAG-His6 at the C-terminus for the preparation of nanobodies. Unconjugated and unwanted products are removed using diafiltration.

[0141] AAV2 allows LPQTG [SEQ ID NO: 43] to be inserted into loops IV and VIII with different linker lengths. The LPQTG motif [SEQ ID NO: 43] was inserted into AAV2-HB0 VR-IV (between AA453 and 454) VR-VIII (between AA587 and 588) with no linker or with 1 or 2 GGSGS [SEQ ID NO: 47] repeats on either side of the motif. Next, Gly5-Nanobody was conjugated using sortase A. Western blotting was performed and imaging was performed using anti-VP antibody (detecting VP1, 2, and 3) and anti-FLAG antibody (detecting nanobody). Since the sortase A reaction cleaves the primary structure of VP during the conjugation process, a band of 17-18 kDa is expected to appear in VIII-1 and VIII-2 ( Figure 3 ).

[0142] Example 2: AAV2_VR-I 0-2L

[0143] Materials and methods

[0144] AAV vectors (SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15) containing LPQTG [AAV2-HB0 carries an LPQTG tag at position 265, with 0, 1 or 2 GGSGS linkers on both sides of the tag], as well as sortase A and anti-GFP nanobody (SEQ ID NO: 11) in 1x sortase reaction buffer (300mM Tris, 150mM NaCl, 5mM CaCl2, pH7.5). The molar concentration of sortase A is 100 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody is 100 times higher than that of AAV viral proteins. The mixture was incubated at 25°C for 16 hours. The reacted samples, together with an equal amount of vector in sortase reaction buffer without sortase A or nanobody, were then run on SDS-PAGE gel and blotted to PVDF membrane. After blocking, the membrane was incubated with 1:1000 rabbit anti-VP1 / 2 / 3 (Progen #61084) for 16 hours at 4° C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-rabbit antibody (Dako P0448) for 1 hour at room temperature and developed using chemiluminescence.

[0145] At the same time, an equal amount of unreacted nanobody was loaded on a separate SDS-PAGE gel, which was blotted onto a PVDF membrane and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) for 16 h at 4°C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) for 1 h at room temperature and developed using chemiluminescence.

[0146] Results and Discussion

[0147] In the anti-VP1 / 2 / 3 stained blots of the nanobody-conjugated samples ( Figure 4 ), a faint band above the 55 kDa reference band is visible (arrowhead), with increasing intensity as linker length increases from 0 to 1 to 2 GGSGS [SEQ ID NO: 47] elements. This apparent molecular mass is consistent with sortase A-mediated strand cleavage, generating a 53 kDa C-terminal VP fragment.

[0148] Likewise, a faint band above the 35 kDa marker was visible, which could point to the Nanobody-conjugated VP1 or VP2 fragments. However, the 100-fold excess of Nanobody and the unknown 40 kDa species in the Nanobody preparation made identification of fainter bands difficult.

[0149] In summary, the LPQTG tag [SEQ ID NO: 43] can be inserted into VR-I, but the conjugation efficiency is low. The conjugation efficiency increases with the increase of linker length, although the efficiency is generally low at this insertion site.

[0150] Example 3: AAV2_VR-IV 0-5L

[0151] Materials and methods

[0152] AAV vectors containing LPQTG (SEQ ID NO: 16 to SEQ ID NO: 20) [AAV2-HB0 with LPQTG tag at position 453, flanked by 0, 1, 3, 4 or 5 GGSGS linkers], sortase A and anti-GFP nanobody (SEQ ID NO: 11) were prepared in 1x sortase reaction buffer (300 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.5). The molar concentration of sortase A was 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody was 100 times higher than the molar concentration of AAV viral proteins. The same reaction mixture, but without sortase A and nanobody, was also prepared. The reaction mixture was incubated at 25°C for 16 hours. The samples were then run on SDS-PAGE gels and blotted onto PVDF membranes. After blocking, the membrane was incubated with 1:1000 rabbit anti-VP1 / 2 / 3 (Progen #61084) at 4°C for 16 hours. After washing, the gel was incubated with 1:10,000 HRP-conjugated goat anti-rabbit antibody (Dako P0448) at room temperature for 1 hour and developed using chemiluminescence.

[0153] In parallel, the reaction mixture was loaded on a separate SDS-PAGE gel, which was blotted onto a PVDF membrane and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) for 16 h at 4° C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) for 1 h at room temperature and visualized using chemiluminescence.

[0154] Results and Discussion

[0155] In the anti-VP1 / 2 / 3 stained blot of the Nanobody-conjugated samples, a clear band at 37-39 kDa was clearly visible ( Figure 5 ). The intensity increases from 0 to 1 to 3 linker repeats and appears to level off as linker length increases to 4 to 5 linker repeats. Given that most fragments migrate slightly above their expected molecular weights, this apparent molecular mass is consistent with sortase A-mediated strand cleavage, generating a 32-35 kDa C-terminal VP fragment.

[0156] Similarly, a band was visible around the 55 kDa marker, indicating the N-terminal VP fragment conjugated to the Nanobody. This band was not visible in the absence of the linker fragment, was barely visible with one linker repeat, but was clearly visible with 3, 4 or 5 linker repeats, with no significant difference in intensity between 3, 4 or 5 repeats.

[0157] In summary, the LPQTG tag [SEQ ID NO: 43] can be inserted into VR-IV of AAV2 with good conjugation efficiency. The conjugation efficiency increases with the increase of linker length and seems to reach a stable state when there are 3 GGSGS linker repeats on each side of the LPQTG tag.

[0158] Example 4: AAV2_VR-VIII 0-5L

[0159] Materials and methods

[0160] AAV vectors (SEQ ID NO: 21 to SEQ ID NO: 26) containing LPQTG [AAV2-HB0 carries a LPQTG tag at position 587, with 0, 1, 2, 3, 4 or 5 GGSGS linkers on both sides of the tag], as well as sortase A and anti-GFP nanobody (SEQ ID NO: 11) in 1x sortase reaction buffer (300mM Tris, 150mM NaCl, 5mM CaCl2, pH7.5). The molar concentration of sortase A is 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody is 100 times higher than that of AAV viral proteins. The same reaction mixture, although without sortase A and nanobody, was also prepared. The reaction mixture was incubated at 25°C for 16 hours. The samples were then run on SDS-PAGE gels and blotted onto PVDF membranes. After blocking, the membrane was incubated with 1:1000 rabbit anti-VP1 / 2 / 3 (Progen #61084) for 16 hours at 4° C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-rabbit antibody (Dako P0448) for 1 hour at room temperature and developed using chemiluminescence.

[0161] At the same time, the reaction mixture was loaded on a separate SDS-PAGE gel with a sample containing only the same amount of nanobodies. It was blotted onto a PVDF membrane and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) at 4°C for 16 hours. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) at room temperature for 1 hour and developed using chemiluminescence.

[0162] Results and Discussion

[0163] In the anti-VP1 / 2 / 3 stained blot of the Nanobody conjugated samples, a clear band at 17-20 kDa was clearly visible ( Figure 6). The intensity increases from 0 to 1 to 3 to 4 linker repeats (with 2 linker repeats having lower intensity), and appears to be lower again at 5 linker repeats. This apparent molecular mass is consistent with sortase A-mediated strand cleavage, generating a 17-20 kDa C-terminal VP fragment.

[0164] Similarly, a band was visible around the 70 kDa marker, indicating the Nanobody-conjugated N-terminal VP fragment, although migrating slightly higher, as was the unreacted VP1 / 2 / 3 band. This band was not visible in the absence of the linker fragment, increased from 0 to 1 to 3 to 4 linker repeats, and was lower again at 5 linker repeats.

[0165] In summary, the LPQTG tag [SEQ ID NO: 43] can be inserted into VR-VIII of AAV2 with moderate conjugation efficiency. The conjugation efficiency increases with increasing linker length and appears to peak at 4 GGSGS [SEQ ID NO: 47] linkers on each side of the LPQTG tag [SEQ ID NO: 43].

[0166] Example 5: AAV9_VR-IV 0-3L

[0167] Materials and methods

[0168] AAV vectors (SEQ ID NO: 27 to SEQ ID NO: 30) containing LPQTG in 1x sortase reaction buffer (300 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.5) [AAV9-A carries an LPQTG tag at position 455, with 0, 1, 2 or 3 GGSGS linkers on both sides of the tag], sortase A and anti-GFP nanobody (SEQ ID NO: 11). The molar concentration of sortase A is 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody is 100 times higher than that of AAV viral proteins. The mixture was incubated at 25°C for 16 hours. The reacted samples, together with an equal amount of vector in sortase reaction buffer without sortase A or nanobody, were then run on SDS-PAGE gel and blotted to PVDF membrane. After blocking, the membrane was incubated with 1:1000 mouse anti-VP1 / 2 / 3 (Progen #65158) at 4°C for 16 hours. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) at room temperature for 1 hour and developed using chemiluminescence.

[0169] At the same time, an equal amount of unreacted AAV and an equal amount of unreacted nanobody were loaded on a separate SDS-PAGE gel, which was blotted onto a PVDF membrane and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) for 16 hours at 4°C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) for 1 hour at room temperature and developed using chemiluminescence.

[0170] Results and Discussion

[0171] In the anti-VP1 / 2 / 3 stained blot of the Nanobody-conjugated sample, a clear band at 39 kDa was clearly visible ( Figure 7 ).

[0172] The intensity increases from 0 to 1 linker repeat and has similar intensity for 1, 2, and 3 linker repeats. Given that most fragments migrate slightly above their expected molecular weight, this apparent molecular mass is consistent with sortase A-mediated strand cleavage, generating a 33 kDa C-terminal VP fragment.

[0173] In the anti-FLAG gel, a band was visible at 45 kDa, indicating the nanobody-conjugated N-terminal VP fragment. This band was not visible in the absence of the linker fragment, but increased in intensity from 1 to 2 to 3 linker repeats.

[0174] In summary, the LPQTG tag [SEQ ID NO: 43] can be inserted into VR-IV of AAV9 with good conjugation efficiency. The conjugation efficiency increases with the increase of linker length and reaches the highest value when there are 3 GGSGS [SEQ ID NO: 47] linkers on each side of the LPQTG tag [SEQ ID NO: 43]. This construct was not tested using longer linker lengths.

[0175] Example 6: AAV9_VR-VIII 0-1-3L

[0176] Materials and methods

[0177] AAV vectors containing LPQTG (SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33) [AAV9-A carries an LPQTG tag at position 589, with 0, 1 or 3 GGSGS linkers on both sides of the tag], as well as sortase A and anti-GFP nanobody (SEQ ID NO: 11) in 1x sortase reaction buffer (300mM Tris, 150mM NaCl, 5mM CaCl2, pH7.5). The molar concentration of sortase A is 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody is 100 times higher than that of AAV viral proteins. The mixture was incubated at 25°C for 16 hours. The reacted samples, together with samples without sortase A, were then run on SDS-PAGE gels and blotted to PVDF membranes. After blocking, the membrane was incubated with 1:1000 mouse anti-VP1 / 2 / 3 (Progen#65158) at 4°C for 16 hours. After washing, the gel was incubated with 1:10,000 HRP-conjugated goat anti-mouse antibody (Dako P0447) at room temperature for 1 hour and developed using chemiluminescence.

[0178] At the same time, we loaded the reaction mixture along with the sample without sortase A onto a separate SDS-PAGE gel, which was blotted onto a PVDF membrane and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) for 16 h at 4°C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) for 1 h at room temperature and developed using chemiluminescence.

[0179] Results and Discussion

[0180] In the anti-VP1 / 2 / 3 stained blot of the Nanobody-conjugated sample, a faint band at 17 kDa was visible ( Figure 8 ). The band with 1 linker repeat was not distinguishable, but increased in intensity from 1 to 3 linker repeats. This apparent molecular mass is consistent with sortase A-mediated strand cleavage, generating a 17 kDa C-terminal VP fragment.

[0181] In the anti-FLAG gel, a band was visible at 70 kDa, indicating the nanobody-conjugated N-terminal VP fragment. This band was very faint in the absence of the linker fragment, but increased in intensity from 1 to 3 linker repeats.

[0182] In summary, the LPQTG [SEQ ID NO: 43] tag can be inserted into VR-VIII of AAV9, but the conjugation efficiency is low. The conjugation efficiency increases with the increase of linker length and reaches the highest value when there are 3 GGSGS [SEQ ID NO: 47] linkers on each side of the LPQTG tag [SEQ ID NO: 43]. This construct was not tested using longer linker lengths.

[0183] Example 7: AAV2_VR-I 2L, AAV2_VR-IV 3L, AAV2_VR-VIII 3L, AAV9_VR-IV 3L and AAV2_VR-VIII 3L

[0184] Materials and methods

[0185] AAV vectors containing LPQTG (SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 30, SEQ ID NO: 33) [AAV2-HB0 with a LPQTG tag at position 265, with two GGSGS linkers on each side of the tag; AAV2-HB0 with a LPQTG tag at position 453, with three GGSGS linkers on each side of the tag; AAV2-HB0 with a LPQTG tag at position 587, with three GGSGS linkers on each side of the tag; AAV9-A with a LPQTG tag at position 455, with three GGSGS linkers on each side of the tag and AAV9-A with a LPQTG tag at position 589, with three GGSGS linkers on each side of the tag] were incubated with sortase A and anti-HER2 nanobody (SEQ ID NO: 12) in 1x sortase reaction buffer (300 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 5.0). 7.5). The molar concentration of sortase A was 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobodies was 100 times higher than that of AAV viral proteins. The mixture was incubated at 25°C for 16 hours. The reacted samples, together with an equal amount of vector in sortase reaction buffer without sortase A or nanobodies, were then run on an SDS-PAGE gel and blotted to a PVDF membrane. After blocking, the membrane was incubated with 1:1000 rabbit anti-VP1 / 2 / 3 (Progen#61084) at 4°C for 16 hours. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-rabbit antibody (DakoP0448) at room temperature for 1 hour and developed using chemiluminescence.

[0186] In parallel, the reaction mixture was loaded on a separate SDS-PAGE gel, which was blotted onto a PVDF membrane and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) for 16 h at 4° C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) for 1 h at room temperature and visualized using chemiluminescence.

[0187] Results and Discussion

[0188] In the anti-VP1 / 2 / 3 stained blot, several bands related to the C-terminal VP fragment generated by sortase A are visible ( Fig. 9 ). For AAV2_VR-I, the band at ˜58 kDa is quite faint, indicating ineffective coupling. For AAV2_VR-IV and AAV9_VR-IV, the band at ˜38 kDa is clearly visible, indicating effective coupling. For AAV2_VR-VIII and AAV9_VR-VIII, the band at ˜18 kDa is more intense than AAV2_VR-I, but less intense than AAV2_VR-IV and AAV9_VR-IV, indicating intermediate coupling.

[0189] The same findings were also reflected in the FLAG-stained blots. The bands corresponding to conjugated AAV2_VR-I and AAV9-VR-VIII were completely obscured by the background of the nanobody. The bands corresponding to conjugated AAV2_VR-VIII were very faintly visible. The bands corresponding to AAV2_VR-IV and AAV9_VR-IV were clearly visible.

[0190] In summary, insertion into VR-IV showed the highest coupling efficiency. Insertion into VR-VIII did appear to be effective, albeit at a lower efficiency, and insertion into VR-I was possible, albeit with very low relative efficiency.

[0191] Example 8: GGG-biotin

[0192] Materials and methods

[0193] AAV vector containing LPQTG (SEQ ID NO: 22 (587_1L_pdAAVe_008)) [AAV2-HB0 with LPQTG tag at position 587, flanked by 1 GGSGS linker] was incubated with sortase A and biotinylated GGG peptide (GGG-[K(biotin)]-amide, Cambridge Research Biochemicals, crb1000649h) in 1x sortase reaction buffer (300 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.5). The molar concentration of sortase A was 100-fold higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of GGG-biotin peptide was 250-fold higher than the molar concentration of AAV viral proteins (sample (1)). Control samples included (2) "no AAV", (3) no sortase A, (4) no GGG-biotin peptide, (5) GGG-biotin peptide only, (6) GGG-biotin peptide with BSA, and (7) BSA only. In the control reactions, the concentrations of all components were the same as in reaction (1), and the mass amount of BSA in samples (6) and (7) was the same as the mass amount of viral protein in sample (1). The reaction mixtures were incubated at 25°C for 16 hours.

[0194] The samples were then run on SDS-PAGE gels and blotted onto PVDF membranes. After blocking, the membranes were incubated with 1:10 000 streptavidin-HRP (ThermoScientific, 21130) and developed using chemiluminescence.

[0195] As a reference for the molecular weight of VP on the gel, samples containing only AAV were included from different bands, blotted and imaged using anti-VP1 / 2 / 3 antibodies.

[0196] Results and Discussion

[0197] In the streptavidin-HRP blot, sortase A-mediated biotin labeling of VP1, 2, and 3 was observed in sample (1), while all negative controls showed no signs of conjugation ( Fig.10 ). A lower molecular mass than the non-conjugated VP is expected due to the removal of the 17 kDa C-terminal fragment.

[0198] Example 9: HER2 and GFP

[0199] Materials and methods

[0200] AAV vectors containing LPQTG (SEQ ID NO: 24, SEQ ID NO: 30) [AAV2-HB0 carries an LPQTG tag at position 453, with three GGSGS linkers on both sides of the tag, and AAV9-A carries an LPQTG tag at position 589, with three GGSGS linkers on both sides of the tag] were incubated with sortase A and anti-HER2 nanobody (SEQ ID NO: 12), anti-GFP nanobody (SEQ ID NO: 11), or no nanobody in 1x sortase reaction buffer (300mM Tris, 150mM NaCl, 5mM CaCl2, pH7.5). The molar concentration of sortase A was 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody was 100 times higher than that of AAV viral proteins. The mixture was incubated at 25°C for 16 hours. The reacted samples were then run on SDS-PAGE gels and blotted onto PVDF membranes. After blocking, the membrane was incubated with 1:1000 rabbit anti-VP1 / 2 / 3 (Progen #61084) for 16 hours at 4° C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-rabbit antibody (Dako P0448) for 1 hour at room temperature and developed using chemiluminescence.

[0201] In parallel, the reaction mixture was loaded on a separate SDS-PAGE gel, which was blotted onto a PVDF membrane and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) for 16 h at 4° C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) for 1 h at room temperature and visualized using chemiluminescence.

[0202] Results and Discussion

[0203] As observed in previous experiments, sortase A-mediated nanobody conjugation of AAV2 (which has a LPQTG [SEQ ID NO:43] insertion at position 587 flanked by three GGSGS [SEQ ID NO:47] linker repeats) was visible but inefficient ( Fig.11 Sortase A-mediated Nanobody conjugation of AAV9 (the AAV9 has a LPQTG [SEQ ID NO: 43] insertion at position 455 flanked by three GGSGS [SEQ ID NO: 47] linker repeats) was visible with good conjugation efficiency.

[0204] Most importantly from this experiment, there appeared to be no difference in conjugation efficiency between the anti-HER2 and anti-GFP nanobodies.

[0205] Example 10: LPQTG and LPETG in AAV2_VR-VIII and AAV9_VR-IV Materials and methods

[0206] AAV vectors containing LPQTG (SEQ ID NO:24, SEQ ID NO:34, SEQ ID NO:30, SEQ ID NO:35) [AAV2-HB0 with a LPQTG tag at position 587, with 3 GGSGS linkers on each side of the tag; AAV2-HB0 with a LPETG tag at position 587, with 3 GGSGS linkers on each side of the tag; AAV9-A with a LPQTG tag at position 455, with 3 GGSGS linkers on each side of the tag, and AAV9-A with a LPETG tag at position 455, with 3 GGSGS linkers on each side of the tag] were incubated with sortase A and anti-HER2 nanobody (SEQ ID NO:12) in 1x sortase reaction buffer (300mM Tris, 150mM NaCl, 5mM CaCl2, pH 7.5). The molar concentration of sortase A was 5 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobodies was 50 times higher than that of AAV viral proteins. The mixture was incubated at 25°C for 20 hours. The reacted samples were run on SDS-PAGE gels and blotted on PVDF membranes. After blocking, the membrane was incubated with 1:500 rabbit anti-VP1 / 2 / 3 (Progen #61084) at 4°C for 16 hours. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-rabbit antibody (Dako P0448) at room temperature for 1 hour and developed using chemiluminescence.

[0207] In parallel, we loaded and ran the reaction mixture on a separate SDS-PAGE gel, blotted onto a PVDF membrane, and stained with 1:1000 mouse anti-FLAG antibody (Novus Bio NBP1-97410) for 16 h at 4° C. After washing, the gel was incubated with 1:10000 HRP-conjugated goat anti-mouse antibody (Dako P0447) for 1 h at room temperature and visualized using chemiluminescence.

[0208] Results and Discussion

[0209] As observed in previous experiments, sortase A-mediated nanobody conjugation of AAV2 (which has a LPQTG insertion at position 587 flanked by three GGSGS [SEQ ID NO: 47] linker repeats) was visible but inefficient ( Fig.12Sortase A-mediated Nanobody conjugation of AAV9 (the AAV9 has a LPQTG [SEQ ID NO: 43] insertion at position 455 flanked by three GGSGS [SEQ ID NO: 47] linker repeats) was visible with good conjugation efficiency.

[0210] From both anti-VP1 / 2 / 3 and anti-FLAG blots, LPETG [SEQ ID NO:44] appears to have a slightly higher conjugation efficiency than LPQTG [SEQ ID NO:43], at least for conjugation of anti-HER2 nanobodies to AAV9, which has an LPXTG [SEQ ID NO:10] insertion at position 455 flanked by 3 GGSGS [SEQ ID NO:47] linker repeats.

[0211] Example 11: In vitro targeting

[0212] Materials and methods

[0213] AAV vector (SEQ ID NO: 24) containing LPQTG [AAV2-HB0 has LPQTG tag at position 587, with 3 GGSGS linkers on both sides of the tag] was incubated with sortase A and anti-HER2 antibody (SEQ ID NO: 12) ("conjugated anti-HER2 Nb"), sortase A and anti-GFP nanobody (SEQ ID NO: 11) ("conjugated anti-GFP Nb"), anti-HER2 nanobody (SEQ ID NO: 12) without sortase A ("unconjugated, with Nb"), and neither nanobody nor sortase A ("unconjugated, without Nb") in 1x sortase reaction buffer (300mM Tris, 150mM NaCl, 5mM CaCl2, pH7.5). The molar concentration of sortase A was 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody was 100 times higher than that of AAV viral proteins. The reaction was incubated at 25°C for 20 hours and then dialyzed against PBS using a Micro Float-A-Lyzer 100 kDa MWCO (Repligen, F235049) to remove sortase A enzyme and unreacted nanobodies. Finally, the viral genome titer was determined using the ddPCR method.

[0214] MCF-10A (HER2 negative) and BT-474 (HER2 positive) cells were cultured in MEBM (Lonza) supplemented with 10% FBS and RPMI1640 (Gibco) medium supplemented with Glutamax and 10% FBS, respectively. Cells were seeded in 90ul culture medium at 50.000 cells and mixed with the vector at an MOI of 1E5 vg / cell in 30ul. The mixture was inoculated in a 96-well plate, and 80ul of culture medium was added after 3 hours. After 72 hours, the cells were washed with PBS, trypsinized, centrifuged (spundown), and the cells were resuspended in 400ul PBS containing 1:10 000 PerCP-Cy5.5 conjugated anti-HER2 antibody (BioLegend 324416). After incubation at room temperature for 30 minutes, the cell suspension was analyzed using an Attune flow cytometer.

[0215] Results and Discussion

[0216] Regardless of the presence or absence of nanobodies, and regardless of whether they were conjugated, the AAV vector containing LPQTG (SEQ ID NO: 24) was unable to transduce MCF-10AHER2-negative cells ( Fig.13 This is most likely a result of the HB0 mutation, as unmodified AAV2 did efficiently transduce MCF-10A cells (86%) at an MOI of 1E5 (data not shown).

[0217] For BT-474HER2-positive cells, the transduction efficiency of AAV vectors conjugated with anti-HER2 nanobody was significantly higher than that of unconjugated vectors or anti-GFP nanobody-conjugated vectors.

[0218] These results clearly demonstrate that conjugation of our vectors with targeting nanobodies can lead to improved transduction efficiency and specificity. Fig.13 A, 13B and 13C).

[0219] Example 12: Comparison of transduction efficiency

[0220] Materials and methods

[0221] AAV vectors containing LPQTG (SEQ ID NO: 24 and SEQ ID NO: 30) [AAV2-HB0 with LPQTG tag at position 587, 3 GGSGS linkers on both sides of the tag and AAV9-A with LPQTG tag at position 455, 3 GGSGS linkers on both sides of the tag] were incubated with sortase A and anti-HER2 nanobody (SEQ ID NO: 12) ("conjugated anti-HER2 Nb"), and anti-HER2 nanobody (SEQ ID NO: 12) without sortase A ("unconjugated, with Nb") in 1x sortase reaction buffer (300mM Tris, 150mM NaCl, 5mM CaCl2, pH 7.5). The molar concentration of sortase A was 10 times higher than the molar concentration of AAV viral proteins in the mixture, while the molar concentration of nanobody was 100 times higher than the AAV viral proteins. The reaction was incubated at 25°C for 20 hours and then dialyzed against PBS using a Micro Float-A-Lyzer 100 kDa MWCO (Repligen, F235049) to remove sortase A enzyme and unreacted nanobodies. Finally, the viral genome titer was determined using the ddPCR method.

[0222] BT-474 (HER2 positive) cells were cultured in MEBM (Lonza) supplemented with 10% FBS and RPMI1640 (Gibco) medium supplemented with Glutamax and 10% FBS. The cells were inoculated in 90ul culture medium at 50.000 cells and mixed with the carrier at an MOI of 1E5 vg / cell in 30ul or in an equal amount of diluted unreacted nano antibodies only. The mixture was inoculated in a 96-well plate, and 80ul of culture medium was added after 3 hours. After 72 hours, the cells were washed with PBS, trypsinized, spun, and the cells were resuspended in 400ul PBS containing 1:10 000 PerCP-Cy5.5 conjugated anti-HER2 antibody (BioLegend324416). After incubation at room temperature for 30 minutes, the cell suspension was analyzed using an Attune flow cytometer.

[0223] Results and Discussion

[0224] The transduction efficiency of AAV vectors conjugated with anti-HER2 nanobodies was 92 times higher (AAV2_VR-VIII 3L, SEQ ID NO: 24) and 8 times higher (AAV9_VR-IV 3L, SEQ ID NO: 30) than that of unconjugated vectors. Fig.14 ).

[0225] The results clearly demonstrate that conjugation of our vector with targeting Nanobodies can lead to improved transduction efficiency.

[0226] Interestingly, the effect was significantly >10-fold greater for AAV2_VR-VIII 3L, which had a lower conjugation efficiency (~2%) than AAV9_VR-IV 3L (~12%). This could be due to the insertion position or the base serotype used.

[0227] Example 13: Comparison of production yields of different constructs

[0228] Materials and methods

[0229] HEK293 cells were seeded at 3.6E+06 viable cells per 10 cm dish in DMEM containing 10% fetal bovine serum and transfected with a transgenic plasmid (encoding ITR-flanked CAG-GFP), a plasmid encoding adenoviral helper genes, and a plasmid encoding rep / cap using PEIpro according to the manufacturer's recommendations. Each of AAV2, AAV9, AAV2-VR-VIII-LPQTG-3L [SEQ ID NO: 24], and AAV9-VR-IV-LPQTG-3L [SEQ ID NO: 30] was transfected in a dual clone manner. The transfected plates were stored at 37°C and 5% CO2, and the medium was replaced with DMEM containing 5% FBS 24 hours after transfection. 72 hours after transfection, the supernatant was collected. The cells were detached using trypsin and stored in a separate falcon tube. Both tubes were spun at 1000g for 5 minutes. Transfer the supernatant of the culture medium to a new tube and discard the supernatant of the cell fraction.

[0230] Next, the cell pellet was lysed using 3 freeze-thaw cycles, treated with DNase for 1 hour at 37°C, and finally centrifuged to remove insoluble debris. Using ddPCR, the viral genome ("Vg") titer from the supernatant and cell fraction was determined. Using ELISA, the viral particle ("Vp") titer from the supernatant and cell fraction was determined.

[0231] Results and Discussion

[0232] Although there was some variability in yield and percentage full, the adherence production of mutant vectors was similar to that of ancestral (AAV2 and AAV9) serotypes ( Fig.15 In other words, insertion of the LPQTG site with 15 amino acids on each side did not result in a significant decrease in yield.

[0233] Sequences mentioned in this application

[0234] AAV2 wild-type Cap

[0235] Starting VP2 T138

[0236] Starting VP3 M203

[0237] VP1-VP2 transition P135-G141

[0238] PVKTAP [SEQ ID NO: 1]

[0239] VR-IS261-N268

[0240] VR-IVS446-S474

[0241]

[0242] VR-VIIIQ575-V600

[0243]

[0244] VP1 [SEQ ID NO:7]

[0245]

[0246] VP2 [SEQ ID NO:8]

[0247]

[0248] VP3 [SEQ ID NO:9]

[0249]

[0250] Mutations R585A and R588A refer to HB 0 Variants

[0251] Recognition motif:

[0252] Xn-LPXTG-Xm

[0253]

[0254] wherein X is any natural AA, or wherein X is DEQN, wherein X is Q.

[0255] n=0-20

[0256] m=0-20

[0257] The surface exposed lysines within 30 angstroms of the VR-I loop are:

[0258] K258 K321 K490 K507 K527 K532 K544 K549 K556 K620 K640 K649 K665 K692K706

[0259] The surface exposed lysines within 15 angstroms of the VR-I loop are:

[0260] K258 K507 K527 K549 K706

[0261] The surface exposed lysines within 30 angstroms of the VR-IV loop are:

[0262]

[0263] The surface exposed lysines within 15 angstroms of the VR-IV loop are:

[0264] K258 K490 K507 K532 K544 K549 K556 K665

[0265] The surface exposed lysines within 5 angstroms of the VR-IV loop are:

[0266] K549

[0267] The surface exposed lysines within 30 angstroms of the VR-VIII loop are:

[0268] K309 K490 K507 K527 K532 K544 K549 K556 K620 K640 K688 K706

[0269] The surface exposed lysines within 15 angstroms of the VR-VIII loop are:

[0270] K490 K507 K527 K532

[0271] The surface exposed lysines within 5 angstroms of the VR-VIII loop are:

[0272] K507

[0273] GFP Nanobody:

[0274]

[0275] HER2 Nanobody:

[0276] AAV2-VR-I-0L

[0277]

[0278] AAV2-VR-I-1L:

[0279]

[0280] AAV2-VR-I-2L:

[0281]

[0282] AAV2-VR-IV-OL:

[0283]

[0284] AAV2-VR-IV-1L:

[0285]

[0286] AAV2-VR-IV-3L

[0287]

[0288] AAV2-VR-IV-4L:

[0289]

[0290] AAV2-VR-IV-5L:

[0291]

[0292] AAV2-VR-VIII-0L:

[0293]

[0294] AAV2-VR-VIII-1L:

[0295] AAV2-VR-VIII-2L:

[0296]

[0297] AAV2-VR-VIII-3L:

[0298] AAV2-VR-VIII-4L:

[0299]

[0300] AAV2-VR-VIII-5L:

[0301]

[0302] AAV9-VR-IV-0L:

[0303]

[0304] AAV9-VR-IV-1L

[0305]

[0306]

[0307] AAV9-VR-IV-2L

[0308]

[0309] AAV9-VR-IV-3L

[0310]

[0311] AAV9-VR-VIII-0L:

[0312]

[0313]

[0314] AAV9-VR-VIII-1L:

[0315]

[0316] AAV9-VR-VIII-3L:

[0317] AAV2-VR-VIII-LPETG-3L:

[0318]

[0319]

[0320] AAV9-VR-IV-LPETG-3L:

[0321]

[0322] VP1 capsid VR-IV region amino acids 453-454

[0323]

[0324] VP1 capsid VR-VIII region amino acids 587-588

[0325]

[0326] VP1 capsid VR-VIII region amino acids 587-588 double linker

[0327] Linker sequence 1: GGGGS [SEQ ID NO: 39]

[0328] Xn-NPXTG-Xm:NPXTG[SEQ ID NO:40]

[0329] Xn-LPXTA-Xm: LPXTA [SEQ ID NO: 41] Xn-LAXTG-Xm: LAXTG [SEQ ID NO: 42] Sortase A recognition sequence 1: LPQTG [SEQ ID NO: 43] Sortase A recognition sequence 2: LPETG [SEQ ID NO: 44] Sortase A recognition sequence 3: LPNTG [SEQ ID NO: 45] Sortase A recognition sequence 4: LPDTG [SEQ ID NO: 46] Linker sequence 2: GGSGS [SEQ ID NO: 47]

[0330] Xn-LPXAG-Xm:LPXAG[SEQ ID NO:48]

[0331] Xn-LPXLG-Xm:LPXLG[SEQ ID NO:49]

[0332] Xn-APXTG-Xm:APXTG[SEQ ID NO:50]

[0333] Xn-LPXSG-Xm:LPXSG[SEQ ID NO:51]

[0334] Xn-FPXTG-Xm:FPXTG[SEQ ID NO:52]

[0335] Xn-XPKTG-Xm:XPKTG[SEQ ID NO:53]

[0336] Xn-LPEXG-Xm:LPEXG[SEQ ID NO:54]

[0337] Xn-NPQTN-Xm:NPQTN[SEQ ID NO:55]

[0338] Xn-QVPTG-Xm:QVPTG[SEQ ID NO:56]

[0339] Xn-LPNTA-Xm:LPNTA [SEQ ID NO:57]

[0340] Xn-LPLTG-Xm:LPLTG [SEQ ID NO:58]

[0341] Xn-APKTG-Xm:APKTG[SEQ ID NO:59]

[0342] Xn-DPKTG-Xm DPKTG[SEQ ID NO:60]

[0343] Xn-SPKTG-Xm:SPKTG[SEQ ID NO:61]

[0344] Xn-APATG-Xm:APATG[SEQ ID NO:62]

[0345] Xn-LAETG-Xm:LAETG[SEQ ID NO:63]

[0346] Xn-LPEAG-Xm:LPEAG[SEQ ID NO:64]

[0347] Xn-LPECG-Xm:LPECG[SEQ ID NO:65]

[0348] Xn-LPESG-Xm:LPESG[SEQ ID NO:66]

[0349] Xn-LMVGG-Xm:LMVGG[SEQ ID NO:67]

Claims

1. Adeno-associated virus (AAV) capsid protein, characterized in that A sortase recognition sequence is inserted in one or more of the VP1-VP2 transition region, the VR-I region, the VR-IV region, or the VR-VIII region.

2. The AAV capsid protein according to claim 1, characterized in that The inserted sortase recognition sequence is a sequence having a universal sequence motif selected from the group consisting of: Xn-LPXTG-Xm [SEQ ID NO: 10], Xn-NPXTG-Xm [SEQ ID NO: 40], Xn-LPXTA-Xm [SEQ ID NO: 41], Xn-LAXTG-Xm [SEQ ID NO: 42], Xn-LPXAG-Xm [SEQ ID NO: 48], Xn-LPXLG-Xm [SEQ ID NO: 49], Xn-APXTG-Xm [SEQ ID NO: 50], Xn-LPXSG-Xm [SEQ ID NO: 51], Xn-FPXTG-Xm [SEQ ID NO: 52], Xn-XPKTG-Xm, [SEQ ID NO: 53] and Xn-LPEXG-Xm [SEQ ID NO: 54]. NO:54], wherein n and m range from 0 to 25, and wherein X is any natural amino acid.

3. The AAV capsid protein according to claim 1 or 2, characterized in that The inserted sortase recognition sequence has the common sequence motif Xn-LPXTG-Xm [SEQ ID NO: 10].

4. The AAV capsid protein according to any one of claims 1 to 3, wherein n and / or m ranges from 0 to 20.

5. The AAV capsid protein according to any one of claims 2 to 4, wherein X is glutamine or glutamic acid.

6. The capsid protein of any one of claims 1 to 5, wherein in the corresponding amino acid sequence in AAV2 or another AAV serotype, the VP1-VP2 transition region is defined by PVKTAP [SEQ ID NO: 1], the VR-I region is defined by SSQSGASN [SEQ ID NO: 2], the VR-IV region is defined by SRTNTPSGTTTQSRLQFSQAGASDIRDQS [SEQ ID NO: 3], and / or the VR-VIII region is defined by QYGSVSTNLQRGNRQAATADVNTQGV [SEQ ID NO: 4].

7. The capsid protein according to any one of claims 1 to 6, wherein in the corresponding amino acid sequence in AAV2 or another AAV serotype, the insertion in the VR-IV region is located in a fragment having TPSGTTTQS [SEQ ID NO: 5], and / or the insertion in the VR-VIII region is located in a fragment having LQRGNRQAA [SEQ ID NO: 6].

8. The capsid protein according to any one of claims 1 to 7, wherein in the region where the sortase recognition sequence LPXTG [SEQ ID NO: 10] is inserted, one or more amino acids in the region are deleted or substituted.

9. The capsid protein according to any one of claims 1 to 8, wherein the AAV is AAV2 or AAV9. 10 . The capsid protein according to claim 1 , wherein n is between 5 and 20, preferably between 5 and 15, more preferably between 10 and 15.

11. The capsid protein according to any one of claims 1 to 10, wherein m is between 5 and 20, preferably between 5 and 15, more preferably between 10 and 15.

12. The capsid protein according to any one of claims 1 to 11, wherein the linker sequence Xn or Xm consists of at least 80% of glycine, serine, threonine and alanine.

13. The capsid protein according to any one of claims 1 to 12, wherein the linker sequence Xm or Xn consists of an amino acid selected from the group consisting of glycine, serine, threonine and alanine.

14. The capsid protein according to any one of claims 1 to 13, wherein X in LPXTG [SEQ ID NO: 10] is aspartic acid, glutamic acid, asparagine or glutamine, preferably wherein X in LPXTG [SEQ ID NO: 10] is glutamine.

15. The capsid protein according to any one of claims 1 to 14, wherein one or more lysine (K) of the AAV capsid protein is mutated to glycine (Gly), serine (Ser) or alanine (Ala), preferably glycine (Gly).

16. A nucleic acid encoding the capsid protein according to any one of claims 1 to 15.

17. An expression vector comprising the nucleic acid of claim 16.

18. An AAV particle comprising the AAV capsid protein according to any one of claims 1 to 15.

19. A conjugated AAV particle comprising an AAV capsid protein characterized by a residual sortase recognition sequence in the VP1-VP2 transition region, the VR-I region, the VR-IV region and / or the VR-VIII region, and wherein the residual sortase recognition sequence is operably linked to a heterologous conjugated molecule.

20. The conjugated AAV particle according to claim 19, wherein the ratio of unconjugated capsid AAV protein to conjugated AAV capsid protein is between 1 / 59 and 59 / 1, preferably between 1 / 20 and 20 / 1, preferably between 1 / 10 and 10 / 1, and more preferably between 1 / 5 and 5 / 1.

21. A conjugated AAV particle according to claim 19 or 20, which is operably linked to a heteroconjugate molecule via a residual sortase recognition sequence, wherein the heteroconjugate molecule is characterized by the presence of a terminal tri-glycine amino acid sequence.

22. The conjugated AAV particle of claims 19 to 21 operably linked to a targeting moiety via a residual sortase recognition sequence.

23. The conjugated AAV particle of any one of claims 19 to 22 for use as a medicament.

24. A method for preparing conjugated AAV particles comprising the following steps - contacting the cell with one or more nucleic acids encoding an AAV capsid protein, wherein one or more of the VP1-VP2 transition region, VR-I region, VR-IV region, or VR-VIII region of the AAV capsid protein comprises a sortase recognition sequence; - allowing the cells to assemble multiple AAV capsid proteins into AAV particles and collecting the AAV particles from the cells; and - Contacting the sortase and the heterologous conjugate molecule with the AAV particles.